



NANORX: THE FUTURE OF PHARMACOLOGY IN CANCER DIAGNOSIS AND THERAPEUTICS

Ritik Kumar^{*1}, Rajiv Ranjan¹, Badal Kr. Singh¹, Khushi Singh¹, Suma Tirkey¹ and Rupa Kumari²

¹Scholar, Department of Pharmacy, Faculty of Medical and Sciences, Ranchi College of Pharmacy, Ranchi, Jharkhand-834010.

²Assistant Professor, Department of Pharmacology, Faculty of Medical and Sciences, Ranchi College of Pharmacy, Ranchi, Jharkhand-834010.



***Corresponding Author: Ritik Kumar**

Scholar, Department of Pharmacy, Faculty of Medical and Sciences, Ranchi College of Pharmacy, Ranchi, Jharkhand-834010.

Article Received on 01/07/2025

Article Revised on 22/07/2025

Article Accepted on 12/08/2025

ABSTRACT

Globally, cancer is one of the main reasons of dying and is extremely tough to deal with and diagnose. The several types and variations of the ailment make it a complicated contamination to tackle. Often, a patient identified with most cancers will face a drastic reduction in quality of life, if no longer dying. One of the largest demanding situations concerning most cancers is early detection and toxic treatment options. Over the past few years, the 2 factors had been advanced upon by the employment of nanotechnology via improvements in tumor imaging and reducing toxicity in drug shipping. Various nanocarriers and substances inclusive of liposomes and nanotubes have proven development in goal specificity and superior imaging. They keep wholesome tissue cells to a greater degree and might useful resource in accurately detecting cancer earlier than metastasis.

In this paper, there can be

- (i) An outline of various nanoparticles and their blessings,
- (ii) How nanocarriers are carried out in cancer diagnosis and treatment,
- (iii) The developmental route of nanotechnology methods, and
- (iv) Destiny possibilities of nanotechnology development.

Nano-Rx refers to the application of nanotechnology and nano-engineered materials in pharmacology, enabling groundbreaking advances in cancer diagnosis and treatment. This field is rapidly changing how cancer is detected, monitored, and treated, offering unprecedented precision and potential for improved patient outcomes. The final decade has witnessed extensive advances inside the improvement and alertness of nanotechnology in cancer detection, prognosis, and therapy culminating in the improvement of the nascent area of "most cancers nano-medicine." A nanoparticle as according to the National Institutes of Health (NIH) suggestions is any cloth that is used inside the formula of a drug resulting in a very last product smaller than 1 micron in size. Nanoparticle-primarily based therapeutic systems have gained monstrous reputation because of their capacity to conquer biological limitations, efficiently deliver hydrophobic healing procedures, and preferentially target ailment sites. Currently, many formulations of nano-carriers are applied together with lipid-based totally, polymeric and branched polymeric, metal-primarily based, magnetic, and mesoporous silica. Innovative strategies have been employed to make the most the multicomponent, three-dimensional constructs presenting multifunctional abilities. Engineering such designs allows simultaneous drug shipping of chemotherapeutics and anticancer gene treatment options to web site-unique goals.

KEYWORDS: Nanoparticles, Nano-carriers, Metastasis, Nanotechnology, Mesoporous silica, Nano-engineered, Chemotherapeutics, Anticancer.

1. INTRODUCTION

Cancer is one of the main reasons of death global, posing a primary mission to the healthcare system. Traditional methods of cancer treatment, along with chemotherapy and radiation, frequently lack

specificity, leading to harm of healthy cells and excessive side outcomes. Similarly, early and correct prognosis of most cancers stays hard in lots of cases. These barriers have created a need for extra advanced and targeted approaches in both analysis and

treatment.^[1]

In latest years, nanotechnology has emerged as a promising field in scientific technology. When carried out to pharmacology, it gives upward thrust to a new and progressive region referred to as NanoRx. NanoRx refers to the use of nanoscale materials and technology for developing greater green drug delivery systems and diagnostic tools, specifically for cancer.^[2]

Over the beyond decades, nanotechnology has emerged as a groundbreaking tool in medication, especially in pharmacology. The concept of using nanomaterials for scientific purposes started gaining interest within the 1990s, with the development of nanoscale drug providers like liposomes and polymeric nanoparticles. The utility of nanotechnology in drug development and diagnostics caused the evolution of a brand new subject called NanoRx — using nano-primarily based systems to enhance the shipping, targeting, and efficacy of drugs, especially in complicated diseases like most cancers.^[3]

Nanox systems, such as liposomes, dendrimer, gold nanoparticles, are designed to distribute cancer drugs directly into tumor tissue, reducing damage to normal cells. It improves therapeutic efficiency and reduces side effects. In diagnostics, nanoprobe and contrast agents, facilitates MRI, PET and fluorescence imaging first and more accurate diagnosis, enables the cancer cells to be very sensitive detections.^[3]

The recent progress in nanofarmacology has shown promising results in pre-clinical and clinical studies. Nanobased medications such as DOXIL® (Liposomal Doxorubicin) and Abraxane® (albumin-bound Paclitaxel) are already approved and are used for cancer treatment by demonstrating the practical success of this technique.^[3]

Nanoparticles can be engineered to carry anticancer drugs immediately to tumor cells, improving the drug's effectiveness while decreasing its dangerous outcomes on healthy tissues. In diagnostics, nanoparticles assist in the early detection of cancer via improving imaging strategies and increasing sensitivity and accuracy.^[4]

This project makes a speciality of the role of NanoRx in most cancers pharmacology. It explores how nanotechnology is getting used to design higher drug delivery structures and diagnostic techniques. The purpose is to recognize how NanoRx can improve cancer treatment consequences and constitute the destiny of pharmacological development.

1.1 BACKGROUND

Cancer is a complex and life-threatening disease characterized by uncontrolled growth and the spread of abnormal cells in the body. According to the World Health Organization (WHO), cancer is one of the most

important causes of death globally, which is responsible for around 10 million deaths in 2020 alone. Despite the development of many therapeutic alternatives, the effectiveness of traditional cancer treatments is often limited by poor targeting, systemic poisoning and inability to detect tumors at the initial stage.^[5]

Science of drug action, pharmacology aims to develop a long time safe and more effective treatment. However, traditional drug systems often fail to achieve site-specific actions and result in significant side effects. This limit has urged researchers to detect advanced drug distribution systems that can improve the medical index for cancer. One of the most promising solutions in this challenge is the use of nanotechnology in pharmacology - which gives rise to the concept of Nanox.^[5]

Nanotechnology belongs to the size of the material between 1 and 100 nanometers. In this scale, materials have unique physical, chemical and biological properties that make them very suitable for medical applications. In cancer treatment, nanoparticles can be constructed to identify tumor cells, medications can be properly distributed to the target site, and drug release can be controlled, increasing the effectiveness of treatment by reducing healthy tissue damage.^[6]

In addition to remedy, nanotechnology has revolutionized most cancers diagnostics. Nanoparticles can beautify imaging techniques like MRI, CT scans, and PET scans with the aid of performing as evaluation reagents, allowing for earlier and extra correct detection of tumors. Nanosensors and nanoprobe can also stumble on cancer biomarkers in blood and tissue samples, making non-invasive prognosis greater possible.^[6]

The integration of nanotechnology in cancer pharmacology has already caused the development of numerous FDA-authorized nanoformulations, together with Doxil®, Abraxane®, and Onivyde®, that have tested progressed scientific results. These advancements sign a shift towards extra personalised and particular most cancers remedy, forming the muse of the emerging discipline of NanoRx.^[6]

1.2 OBJECTIVES

- To recognize the function of nanotechnology in pharmacology, especially within the area of most cancers diagnosis and therapeutics.
- To explore numerous sorts of nanocarriers inclusive of liposomes, dendrimers, nanoparticles, and micelles used in most cancers drug shipping systems.
- To study the blessings of NanoRx over traditional most cancers treatments in terms of concentrated on performance, reduced toxicity, and advanced healing effects.

- To study the position of nanotechnology in most cancers diagnosis, such as early detection and stronger imaging techniques.
- To overview approved nano-based totally tablets and formulations presently in scientific use or underneath research for most cancers remedy.
- To identify the challenges and barriers related to the use of nanotechnology in pharmacology, together with toxicity, scalability, and regulatory concerns.
- To compare the destiny capability of NanoRx in customized medicinal drug and its contribution to the advancement of most cancers pharmacotherapy.

1.3 Scope of the Study

- This study specializes in the developing function of nanotechnology inside the area of pharmacology, particularly its programs in cancer diagnosis and therapeutics. The scope consists of:
 - Understanding primary ideas of nanotechnology and its integration into drug design and shipping for oncology.
 - Exploration of diverse nanocarrier systems which includes liposomes, polymeric nanoparticles, dendrimers, micelles, and gold nanoparticles used for targeted drug shipping in most cancers remedy.
 - Evaluation of NanoRx in cancer prognosis, including the use of nanosensors, quantum dots, and nano-more desirable imaging retailers for early detection and sickness monitoring.
 - Analysis of presently accredited nanoformulations and ongoing scientific trials to assess the realistic effect of NanoRx in actual-international most cancers treatment.
 - Discussion on pharmacokinetic and pharmacodynamic enhancements delivered about by way of nanocarrier systems compared to

traditional chemotherapy.

- Consideration of limitations and demanding situations which include toxicity, manufacturing complexity, price, and regulatory hurdles associated with nanomedicine.
- Assessment of future instructions, which includes customized nanomedicine, clever nanocarriers, and multifunctional theranostic systems.

LITERATURE REVIEW

Nanotechnology has revolutionized the field of medicine, especially in pharmacology and oncology. Over the past two decades, several studies have highlighted the potential of nanomaterials in improving drug delivery and cancer diagnosis. The integration of nanotechnology into pharmacology—referred to as **NanoRx**—has led to the development of advanced drug delivery systems and diagnostic tools with enhanced precision, specificity, and safety.

2.1 Nanotechnology in Drug Delivery

According to Ferrari (2005), nanoparticles can overcome biological limitations and deliver tablets without delay to tumor cells, decreasing off-target effects and enhancing therapeutic effects. Nanocarriers which includes liposomes, polymeric nanoparticles, solid lipid nanoparticles, dendrimers, and micelles have been significantly studied for their ability to encapsulate anticancer capsules and beautify their bioavailability.^[7]

Doxil® (liposomal doxorubicin) is the first FDA-approved nanodrug for most cancers remedy. Studies by way of Barenholz (2012) demonstrated its progressed protection profile and longer circulation time as compared to standard doxorubicin. Similarly, Abraxane® (albumin-bound paclitaxel) confirmed superior efficacy in metastatic breast most cancers due to its improved permeability and retention (EPR) effect.^[7]




Fig. 1 The Criteria Nanoparticles Need to Fulfill to Be Effective Carriers for Chemotherapeutic Drugs. (A) The nanoparticle carrier must bind or contain the desired chemotherapeutic drug(s). (B) The nanoparticle -drug

complex must remain stable in the serum to allow for the systemic delivery of the drug. (C) The nanoparticle - drug complex must be delivered only to tumor cells. (D) The nanoparticle must be able to release the drug once at the site of the tumor. (E) After drug delivery, the residual nanoparticle carrier must be safely degraded.

2.2 Targeted Drug Delivery and Tumor Targeting

Peer-reviewed research by Allen and Cullis (2013) explains how nanoparticles can be functionalized with ligands or antibodies that specifically bind to receptors overexpressed on cancer cells. This **active targeting** increases drug accumulation at the tumor site while minimizing systemic toxicity.^[8]

In addition, the **EPR effect**, first described by Maeda et al. (2000), plays a key role in **passive targeting** by allowing nanoparticles to accumulate more in tumor tissue due to leaky vasculature and poor lymphatic drainage.^[8]

2.3 Nanotechnology in Cancer Diagnosis

Diagnostic nanotechnology has stepped forward unexpectedly. Quantum dots, gold nanoparticles, and magnetic nanoparticles are being used as assessment retailers in imaging strategies like MRI, PET, and fluorescence imaging. Gao et al. (2004) verified the use of quantum dots for real-time tracking of cancer cells in vivo, permitting early and correct tumor detection.

Nanosensors capable of detecting most cancers biomarkers in blood, urine, or tissue samples had been evolved to improve the sensitivity of diagnostic tests. These structures promise non-invasive, speedy, and accurate most cancers detection.

2.4 Theranostics and Personalized Medicine

The idea of theranostics, which mixes remedy and diagnostics in a unmarried nanosystem, has opened new avenues for customized most cancers remedy. As described by Xie et al. (2010), such platforms permit simultaneous imaging, drug transport, and tracking of healing response, presenting real-time comments and manipulate.

2.5 Challenges and Future Perspectives

Despite the promising effects, there are demanding situations. Kesisoglou et al. (2020) discuss troubles like nanoparticle toxicity, complexity of massive-scale production, high fees, and absence of clean regulatory tips. More scientific trials and lengthy-term protection studies are wished before substantial adoption.

However, ongoing research and technological advancements retain to assist the capability of NanoRx in reshaping the future of cancer pharmacotherapy. As we move towards precision medicine, NanoRx offers a pathway to safer, more powerful, and patient-precise treatment strategies.

AIMS AND OBJECTIVES

Aim

To discover and evaluate the role of nanotechnology-based drug delivery and diagnostic structures (NanoRx) in improving the effectiveness, protection, and precision of cancer pharmacotherapy and prognosis.

Objectives

- To understand the fundamental principles of nanotechnology and its integration into cutting-edge pharmacological practices, specifically in oncology.
- To observe diverse nanocarrier systems which include liposomes, dendrimers, nanoparticles, micelles, and gold nanoparticles used in most cancers drug transport.
- To evaluate the blessings of NanoRx over conventional cancer treatments in phrases of targeted drug shipping, decreased toxicity, and progressed healing efficacy.
- To explore the position of nanotechnology in most cancers prognosis, together with the use of nanoparticles in imaging and biosensing for early detection.
- To assessment FDA-accredited nano-based formulations and modern-day scientific trials related to NanoRx in most cancers remedy.
- To pick out the limitations and demanding situations confronted inside the improvement, protection, scalability, and law of nanotechnology in pharmacology.
- To check future possibilities of NanoRx in personalised and precision medicine for most cancers care.

3. MATERIALS AND METHODS

Since this thesis is a **literature-based research study**, it does not involve laboratory experiments or practical testing. The methodology followed for conducting this study is based on **systematic review and analysis of secondary data** from scientific and academic sources.

3.1 Type of Study

- Descriptive, qualitative, and analytical assessment based on secondary data.
- The take a look at consists of comparative evaluation of various nanocarrier structures and their programs in most cancers pharmacology.

3.2 Sources of Data

- Data and facts have been accumulated from the subsequent credible resources:
- Peer-reviewed journals (e.G., Journal of Controlled Release, International Journal of

Nanomedicine, Cancer Nanotechnology, Nature Nanotechnology)

- Textbooks associated with nanotechnology, pharmacology, and oncology
- Research articles and evaluate papers posted in databases like:
 - PubMed
 - ScienceDirect
 - Scopus
 - Google Scholar
- Official websites of agencies along with:
 - World Health Organization (WHO)
 - U.S. Food and Drug Administration (FDA)
 - National Cancer Institute (NCI)

3.3 Inclusion Criteria

- Studies and evaluations published in English.
- Articles from the year 2000 to 2025.
- Publications targeted on nanotechnology in most cancers analysis or remedy.
- Research related to FDA-accredited nanoformulations or the ones in clinical trials.

3.4 Exclusion Criteria

- Non-scientific articles or non-peer-reviewed content material.
- Studies unrelated to pharmacology or most cancers.
- Articles published earlier than 2000 until traditionally relevant.

3.5 Data Analysis

- Collected data have been seriously analyzed and organized into categories:
 - Types of nanocarriers
 - Mechanism of drug delivery
 - Role in cancer analysis
 - Clinical outcomes and safety
 - Comparative evaluation of nano-based vs. Conventional systems changed into blanketed.
- Key findings had been supplied the usage of tables, flowcharts, and figures anyplace relevant.

3.6 Ethical Considerations

- As this research is based totally on published literature and secondary statistics, there have been no ethical issues or requirements for moral clearance.

4. ANTICANCER DRUGS

Anticancer medicine, regularly referred to as an antineoplastic drug, is any drug this is a hit in treating malignant or cancerous illnesses. Anticancer drugs are categorized into numerous sorts, which include alkylating sellers, antimetabolites, herbal materials,

and hormones. Furthermore, there are numerous medications that don't fall into these categories but have anticancer activity and are for that reason utilized in most cancers treatment. Chemotherapy is occasionally flawed for the usage of anticancer tablets, although it refers to chemical substances used to treat ailments in widespread. Mechlorethamine, a nitrogen mustard that was discovered to be effective in treating lymphomas in the 1940s, turned into one of the first tablets used clinically in contemporary remedy to treat most cancers. In 1956, antimetabolite methotrexate turned into the primary pharmaceutical to treat solid tumors. The following 12 months, 5-fluorouracil turned into the first of a brand new own family of tumor-combating remedies, known as first pyrimidine analogs. Since then, numerous anticancer pills were evolved and used with high-quality fulfillment.^{[9][10]}

Cytotoxic medicines, hormones, and signal transduction inhibitors are 3 forms of prescribed drugs. All alkylating sellers, antibiotics, antimetabolites, and other pills are cytotoxic, which destroys cells, specially dividing cells. As a result, all of the terminology and large ideas practice to cytotoxic pills. Hormonal medications deal with malignancies that have an effect on hormone-sensitive organs, consisting of the breast and prostate. Some drugs do now not usually fall neatly into these two classes.^{[9],[10]}

DNA alkylating medicinal drugs are nevertheless utilized to deal with most cancers, regardless of their toxicity. The prevailing notion is that unexpectedly proliferating tumor cells disclose greater unmarried-stranded DNA, making them extra sensitive to alkylating tablets. As our understanding of DNA repair pathways expands, it becomes clean that defective DNA repair, a trademark of most cancers, plays a position in figuring out the therapeutic window of those dangerous pills. Although novel alkylating patterns are unlikely to enter scientific trials, these medicinal drugs have furnished us with better know-how of the therapeutic potential of concentrated on the DNA damage repair pathway.^{[9][10]}

Several previously permitted drugs for makes use of aside from most cancers remedy have these days been found out to have cytostatic results on most cancers cells. Because those capsules have already been examined for toxicity in human beings and animals, they might be without difficulty repurposed as anticancer treatment options. Among the recently diagnosed likely cytostatics are benzimidazole anthelmintics (albendazole, mebendazole, flubendazole), antihypertensive capsules (doxazosin, propranolol), psychopharmaceuticals (chlorpromazine, clomipramine), and anti-diabetic remedy (metformin, pioglitazone).^{[9][10]}

More anti-tumor medicines are being evolved because

of the accelerated prevalence of cancer. From 2015 to 2020, fifty-six novel small-molecule anticancer medicines had been legal and categorised into ten agencies based totally on their anti-tumor goal houses. TKIs (30 medicines), MAPK inhibitors (3 tablets), CDK inhibitors (three capsules), PARP inhibitors (three drugs), PI3K inhibitors (three tablets), SMO receptor antagonists (2 capsules), AR antagonists (2 pills), SSTR inhibitors (2 drugs), IDH inhibitors (2 tablets), and others are examples of those (6 capsules). PTK inhibitors (30/56) are among them, and that they have ended in a paradigm exchange in cancer treatment, with decreased toxicity and greater efficiency.^{[9][10]}

Tyrosine kinase inhibitors (TKIs) can therefore be divided into many types, which include anaplastic lymphoma kinase (ALK).^[11] Fms-like tyrosine kinase (FLT3) is a receptor tyrosine kinase that plays a position in the pathogenesis of acute myeloid leukemia (AML). EGF receptors (EGFR) are mobile-surface receptors belonging to the ErbB circle of relatives of tyrosine kinase, and vascular endothelial boom thing inhibitors (VEGF) play a critical role in angiogenesis, which promotes mobile survival. The growth and proliferation of endothelial cells through binding to particular receptors (VEGFR-1, VEGFR-2, neuropilin), the smoothened (SMO) receptor, a member of the G protein-coupled receptor own family, has emerged as an attractive healing target for the remedy and prevention of human cancers, fibroblast boom thing receptor inhibitors, and Tropomyosin receptor kinase inhibitors.^[12]

Similar to the vesicles shaped via lipids (liposomes), amphiphilic block copolymers form vesicles containing an aqueous compartment inside the middle that encapsulate and shield pills, peptides, proteins, and enzymes. A glucose oxidase loading polymersome-based nanoreactor was constructed by using self-assembling PEG-block-phenylboronic ester or piperidine-functionalized methacrylate PEG-b-(P(BEM-co-PEM)). Such a nanoreactor is inactive in regular tissues, whereas it's miles activated within the tumor via its acidic pH (~6.4), thereby growing tumor oxidative strain via producing hydrogen peroxide with the aid of the catalysis of glucose oxidase. Meanwhile, accelerated hydrogen peroxide induces the self-destruction of nanoreactor-releasing quinone methide to dissipate glutathione levels, in the

long run suppressing the antioxidant ability of tumor cells. As a end result, the nanoreactor correctly damages cancer cells and ablates tumor increase thru the synergistic effect.^[13]

The mitogen-activated protein kinase cascade (MAPK/ERK pathway) is a signaling device this is induced in reaction to diverse stimuli to adjust the proliferation and survival of numerous eukaryotic cells and malignant cells.^[14]

Cyclin-established protein kinases (CDKs) are consultant Thr/Ser phosphokinases that play multifaceted roles in vital cellular equipment in organisms.^[15] Dysfunctions of these multifunctional CDKs have been established to make a contribution to extreme illnesses, together with most cancers, Alzheimer's, Parkinson's disorder, and strokes.^{[16][17]}

Phosphatidylinositol three-kinase (PI3K) is an enzyme that phosphorylates phosphatidylinositol (PI) at its 3-hydroxyl role to produce phosphatidylinositol 30-phosphate.^[18] Aberrant activation of the PI3K/AKT/mTOR (Mammalian target of rapamycin) pathway has been related to many human most cancers sorts.^{[19][20]}

The androgen receptor (AR) is a ligand-established transcriptional issue and an important healing goal for prostate cancer. Competitive binding of antagonists to AR can alleviate the aberrant activation of AR in prostate cancer.^{[21][22]} Chemotherapeutic agents, together with Camptothecin, Methotrexate, Paclitaxel, and DOX, were coupled to Somatostatin receptor (SSTR) SSTR2-preferential SST analogs, showing huge SSTR-selective anti-tumor skills in many distinct sorts of tumors.^[23]

Histone deacetylase (HDAC) enzymes, together with histone acetylase, manipulate modifications to core histone acetylation.^[24] Increased HDAC degrees had been pronounced in numerous human tumors and most cancers mobile traces, which include the MM. HDAC inhibitor vicinity class of antineoplastic dealers targeting the epigenome, particularly chromatin transforming, ensuing in modulation of genes accountable for apoptosis, cellular cycle law, and hyperacetylation of many non- histone proteins.^[25]

Table 1: Different approaches to the treatment of cancer.

Approach	Refs
Oncolytic viruses, along with conventional chemo- and radiotherapy	[26]
Cytokine-based therapies are harnessed to enhance the activity or alleviate the immune-related toxicities of other treatments as well as to target early-stage cancers.	[27] [28]
Monoclonal antibodies have been used extensively in the treatment of cancer, but their use is still limited by several factors, such as tumor penetration and cost. A number of nanobodies have been developed and evaluated at different stages of clinical trials for cancer treatment.	[29]

Therapeutic targeting of non-coding RNAs (ncRNAs) represents an attractive approach for the treatment of cancer, as well as many other diseases.	[30]
Oncolytic virotherapy is a therapeutic approach that uses replication-competent viruses to kill cancers. It involves using viruses to selectively replicate in cancer cells, leading to direct cell lysis and the induction of an anticancer immune response.	[31]
p53-targeted therapy involves restoring/reactivating wild-type p53 or removing mutant p53.	[32]
Synthetic lethality targets the loss of function of tumor suppressor, and despite their toxicity, DNA repair genes, as well as amplification and/or overexpression of genes that cannot be directly targeted.	[33]
Nanotechnology approaches	[34] [35]
G-protein-coupled receptors (GPCRs) are being considered as cancer treatment targets.	[36]
Human papillomavirus (HPV)-related malignancies and tumor microenvironment	[37]

Approach	Refs.
Virotherapy uses live viruses as a cancer treatment. Advances in molecular biology and virology have boosted cancer virotherapy research.	[38]
Clustered regularly interspersed short palindromic repeats (CRISPR/Cas9)	[2]
RNA interference	[39]
Cell-secreted nanovesicles (exosomes)	[40]
Metabolic therapy	[41] [42]
Nanotechnology-based techniques to target cancer mitochondria show promise in cancer therapy.	[43]
Bacteria-influenced tumor immune microenvironment	[44]
Photodynamic therapy is a non-invasive, highly selective cancer treatment.	[45]
The anti-angiogenic gene delivery inhibits the new tumor vasculature formation, thereby abolishing the nutrient and oxygen supply to the tumor cells.	[46]
Suicide gene therapy kills the cancer cells by introducing suicide-inducing transgenes encoding enzymes that convert the prodrug into an active drug locally at the tumor site.	[47]

5. Nanocarriers For Oncology

Nanocarriers are nanoscale drug transport systems designed to move healing dealers specifically to cancer cells even as minimizing damage to wholesome tissues. In oncology, nanocarriers play a

crucial role in enhancing the efficacy, protection, and specificity of anticancer tablets. These companies can beautify drug solubility, stability, circulation time, and targeting potential, offering a sizable advancement over conventional chemotherapy.^[48]




Fig. 1: Different types of nanocarriers.

5.1 LIPOSOMES

Liposomes are spherical vesicles composed of phospholipid bilayers. They can encapsulate each hydrophilic and lipophilic capsules, providing

controlled release and decreased systemic toxicity.

Conventional liposomes are round amphiphilic phospholipid vesicles, about 25 nm–2500 nm in size

that can protect hydrophobic or hydrophilic materials from aqueous or non-aqueous environments, respectively, by using forming a closed bilayer across the cloth.

This specific feature is beneficial for the shipping of both hydrophobic and hydrophilic chemotherapy to targeted websites. For mechanisms of shipping and composition, there are 5 instructions of liposomes that can be utilized to optimize a product's likelihood of achieving supposed outcomes.

These classes are pH-sensitive, cationic, conventional, long-circulating, and immuno-liposomes. PH- touchy liposomes stabilize while the outside pH is altered, normally from a slightly alkaline or impartial pH to an acidic pH, which makes them strong at the physiological pH of 7.4.^[49]

However, the pH-sensitive liposomes dissociate and release their content within the tumor, inflamed, or inflamed areas, which show off acidic properties. Cationic liposomes are made the usage of undoubtedly charged lipids and can interact with negatively-charged compounds in the body like DNA. They may be used for the shipping of vaccines towards cancer by means of loading synthetically lengthy peptides into the liposomes to be delivered to dendritic cells, subsequently improving immune reaction.^[50]

Conventional liposomes were the first technology of liposomes and include a lipid bilayer. The bilayer can be neutral, cationic, or anionic phospholipids in addition to cholesterol, which encompasses the aqueous volume. The essential disadvantage of traditional liposomes is their rapid elimination from the blood.^[51]

Example: Doxil® – a liposomal method of doxorubicin authorised for ovarian and breast cancer.

4.2 Polymeric Nanoparticles

These are biodegradable and biocompatible debris made from polymers like PLA, PLGA, or PEG. They offer sustained and focused delivery and may be surface-functionalized for lively targeting.

Polymeric nanoparticles are colloidal and strong nanostructures constructed of natural or artificial polymers. This is probably of the storage range (nanocapsules), which dissolve/disperse bioactive molecules inside the polymer middle, or of the substance range (nanospheres), which entraps bioactive molecules within the polymer matrix (Figure 1). In this context, polymeric nanoparticles may be carried out as drug motors for cancer treatment. The important sorts of polymeric nanocarriers are illustrated in Figure 2.^[52]




Fig. 2: Types of polymeric nanoparticles.

This polymeric nanocarrier outperforms other nanocarriers in phrases of consistency, drug payload, half of-life time in systemic flow, and sustained drug transport.

More unique characteristics of polymeric nanoparticles are their super synthetic versatility, which allows the researcher to customize them in keeping with the requirements or final aims. Polymeric design may be carried out directly on biopolymers through chemical derivatization to perform specific homes.^[53]

Another choice is the guidance of artificial polymers

from their corresponding monomers, taking into account a huge range of structures and packages. However, those artificial materials may be poisonous due to the difficulty of getting rid of their residuals from the biosystem. Therefore, natural biodegradable polymers, which includes chitosan, protamine, gelatin, albumin, and hyaluronic acid, are now getting used and are regarded to reduce toxicity and decorate biocompatibility. Table 1 summarizes the standard drugs and their nanocarriers in numerous cancers.^[54]

Example: Cisplatin-loaded PLA nanoparticles.

Table 2: Drugs and their used nanocarriers in different cancers.

Polymer	Drug	Type of Cancer	Experimental Model	Refs [*]
Chitosan	Quercetin	Colon cancer	In vivo	[55]
Chitosan/protamine	Curcumin and doxorubicin	Breast cancer	In vitro	[56]
Albumin	Gemcitabine	Pancreatic cancer	In vitro	[57]
Albumin	Carnosic acid	Pancreatic cancer	In vitro	[58]
Gelatin	Paclitaxel	Colon cancer	In vitro	[59]
poly lactic acid	Cisplatin and Chloroquine	Oral Squamous Cell Carcinoma	In vitro	[60]
Hyaluronic acid (HA)	Paclitaxel	Ovarian Carcinoma	In vitro	[61]
Poly lactide-co-glycolide (PLGA)	doxorubicin	various	In vivo	[62]
polyethyleneimine–Polylactic acid (PEI–PLA)	paclitaxel	lung cancer	In vivo	[63]
Polyethylene glycol (PEG)	Camptothecin (CPT)SN38	breast cancer	In vivo	[64]
PLGA-PEG	Paclitaxel	various	In vivo	[65]

4.3. Dendrimers

Dendrimers are highly branched, tree-like polymers with numerous surface functional groups. They allow high drug loading, surface modification, and precise control of drug release.

Dendrimers are large branching molecules with a significant core (activator center) that generates specific fingers (terminal active corporations). Dendrimers can also be made from nucleotides, sugar molecules, and amino acids. They are multivalent, branching, incorporate numerous peripheral agencies, and have a selected molecular weight, making them a one-of-a-type drug delivery automobile. A specific, properly-prepared dendrimer branching sample can be produced via stepwise dendrimer production.^[66]

A generations is a branching level this is included into the center and, while stretched, forms a big outdoor cluster. Hydrophobic bonding, chemical interactions, or hydrogen bonds might all be employed to encapsulate bioactive compounds inside center pores, resulting in progressed outside functioning. Covalent bonds can thus join medicinal compounds with energetic companies at the ends in their chains. These dendrimers have a nicely-described structure that can be successfully adjusted to encapsulate various tablets, which include the anti-tuberculosis medicinal drug rifampicin. Single-generation dendrimers, alternatively, can dissociate the molecules to which they're attached.^[67]

The sample of physiochemical interaction is the number one mechanism of drug–dendrimer binding. This dendrimer has the capacity to be hired in a variety of applications, such as magnetic resonance scanning, targeted remedy, pharmaceutical management, and antiviral and vaccine shipping. It might doubtlessly be used alongside prodrugs. Several anticancer medicines, along with cisplatin and doxorubicin, had been considerably coupled with

dendrimer to provide a greater huge anticancer effect.^[68]

4.4 Solid Lipid Nanoparticles (SLNs)

SLNs combine the advantages of liposomes and polymeric nanoparticles. They provide good stability, protection of labile drugs, and controlled release.

Example: SLNs used for delivery of doxorubicin in breast cancer.

Solid lipid nanocarriers have been used as possible providers for administering lipophilic medicines for the reason that early Nineteen Nineties. Solid lipid nanocarriers are made by dissolving stable lipids in water after which combining them with emulsifiers via micro-emulsification. Solid lipid nanocarriers are organized at room temperature the use of solid lipids, which includes unfastened fatty alcohol or acids; steroids or waxes; mono, di, or triglycerides. The drug molecules may be incorporated into the matrices, crust, or center of the strong lipid relying on the manufacturing conditions and composition.^[69]

This solid lipid nanocarrier has the potential to conquer the restrictions of traditional chemotherapy due to its adaptability. When ionic and hydrophilic drug molecules are blended, the Reticule Endothelial System eliminates the everyday strong lipid nanocarrier, difficult sustained drug launch. Previously, researchers determined a way to integrate ionic and hydrophilic anticancer tablets with lipophilic pharmaceuticals the usage of stable lipid nanocarriers. Polymer–lipid hybrid nanocarriers, as an instance, had been investigated as a capability approach of oral medication administration.^[70]

To solve the drawbacks of typical solid lipid nanocarriers, sure newly created nanocarriers, which include nanostructured lipid companies (a mix of liquid and stable lipids) and lipid drug conjugates (a

water-insoluble service molecule), have been diagnosed. This nanocarrier can be used for medication delivery via topical, injectable, or oral routes. The solid lipid nanocarrier can be used to deliver any healing molecule to a particular vicinity as an exquisite tailored carrier. Various investigations in stable lipid nanocarriers were carried out to act as a automobile for presenting precise nucleic acids or genes, to cure ocular illnesses, for a constrained launch of bioactive materials, and for precisely timed transport of anticancer medicinal medicines.^[71]

4.5 Micelles

Micelles are formed by self-assembly of amphiphilic molecules in aqueous solution. They are ideal for delivering poorly soluble drugs and show excellent stability in the bloodstream. **Example:** Genexol-PM® – paclitaxel-loaded polymeric micelles for breast and lung cancer.

They are amphipathic molecules with a hydrophobic tail that faces the middle and a hydrophilic head that links to the solvents at the out of doors.^[72] Furthermore, an amphoteric molecule can shape an inverted micelle with the top going through the core and the tail closer to the outdoor in a neutral solution.

The length and form of the created micelle nanoparticles are decided by the answer parameters (temperature, ionic power, and pH) and the sort of amphiphilic molecule. Micelle production is decided by the vital micellar concentration (surfactant attention). If the micellar threshold depth is not attained, appropriate micelle manufacturing will now not occur. Polymeric micelles are fashioned in positive solvents by way of two copolymers that collaborate with amphiphilic molecules.^[73]

One copolymer is dissolved by means of the solvent however not the others. The center is generated by using the insoluble copolymer, whilst the periphery is fashioned by using the soluble copolymer, from which the micellar ensemble is fashioned. This polymeric micelle can be used in both industrial and non-commercial settings. In the case of hair follicle illnesses, those polymeric micellar nanocarriers exactly guide the pilosebaceous issue. Adapalene wrapped in a micellar nanocarrier, for instance, boosted its precise efficiency by four.5-fold and 3.Three-fold, respectively, at a modest dosage. Fluorescently categorized aptamers based totally on anti-human.^[74]

4.6 Magnetic Nanocarriers

Magnetic nanocarriers are characterized by the presence of a magnetic core. This magnetic property, along with their modified characteristics, enables their use in biosensing applications. Superparamagnetic nanoparticles exhibit greater sensitivity to magnetic fields compared to paramagnetic nanoparticles. Due to

their magnetic resonance, polymer-coated superparamagnetic iron oxide nanoparticles have been extensively employed as contrast agents in molecular imaging; they also enhance cellular and particle uptake by promoting internalization. Since paramagnetism depends on the absence of a magnetic field, superparamagnetic iron oxides are also used for passive targeting of cancer cells. Examples of magnetic nanoparticles include hematite, maghemite, nano ferrites, and magnetite. These nanoparticles possess unique properties that make them suitable for targeted therapy, gene delivery, and hyperthermia treatment. Attempts have been made to bind epirubicin to ferrofluids to achieve drug accumulation at specific sites. However, achieving deep magnetic field penetration in animal models remains challenging, limiting the use of magnetic nanocarriers for internal applications. Magnetofection describes the application of magnetic nanocarriers in gene and antisense therapies. A size-adjustable nanocarrier encapsulating paclitaxel, known as the Trojan Horse, showed enhanced tumor cell penetration, controlled drug release, and increased cytotoxic effects.^[75]

4.7 Carbon Nanotubes (CNTs)

CNTs have a high surface area and can penetrate cells efficiently. They are studied for drug delivery, gene therapy, and hyperthermia-based treatments.

Carbon nanotubes could have one or many walls. Carbon nanotubes have a extensive range of programs in drug administration due to their amazing residences, together with high aspect ratio, lightweight with high unique surface vicinity, spiky nanostructure advent, and physiochemical, thermodynamic, biomechanical, and electromagnetic talents. Endocytosis is made feasible by means of needle penetration, which allows it to pass past limitations, inclusive of mobile membranes.^[76] Bifunctional nanotubes are hydrophilic and can circulate in the bloodstream for an extended length. In evaluation, non-functionalized carbon nanotubes are toxic and insoluble in water. It can target cancer cells because of its structural consistency, flexibility, and floor modification. Bifunctional carbon nanotubes are regularly hired on this concept to incorporate or hyperlink anticancer drugs, together with Paclitaxel, Mitomycin C, Doxorubicin, Methotrexate, and healing compounds. Carbon nanotubes, aside from clever healthcare, are an amazing resource for a wide variety of packages due to their inherent functions. Graphene is some other vital carbon-based prospective use that is effective in drug delivery.^[77]

4.8 Quantum Dots

They are aquatic nanostructures that release strength. The quantum dot diameter affects luminescence in the UV-near IR range, with thinner nanocrystals (2 nm) emitting blue luminescence and bigger quantum dots (5 nm) emitting purple fluorescence. This mixture of

optical and electric functions, longer luminescence, and significantly lower photostability distinguishes it from other organic dyes. As a result, it's far able to image cells. In mice, as an example, a quantum dot-peptide mixture is used for *in vivo* tumor vascular targeting. To prevent cytotoxicity, a ZnS shell commonly surrounds toxic cadmium in CdSe quantum dots. This boosted the awareness of nanoparticles within the targeted vascular area. These quantum dots were additionally powerful as control and monitoring systems. Surface change of quantum dots, as an example, with encapsulating tumor peptides, effectively attaches to the nucleolin on aberrant cells, growing cellular survival. Furthermore, the mixture of quantum dots with RNA interference has been proven to improve gene suppression. Quantum dots also are used as power transfer quenchers in rate shipping operations, quantum dot-fluorescence resonance energy transfer structures, chemiluminescence-resonance-energy transfer switch acceptors^{[78][79]}, and different programs.

4.9 Mesoporous silica

Mesoporous silica has a large porous honeycomb shape that allows it to be mixed with additional medicinal molecules. It has a huge range of programs inside the biomedical subject due to its ease of use and availability. It can contain both hydrophilic and hydrophobic medicines, which may additionally then be linked to a binding pocket for targeted remedy.^[80] In cancer remedy, mesoporous silica can be employed for both proactive and reactive most cancers focused on. Anticancer drugs, together with camptothecin and methotrexate, are efficiently administered while mesoporous silica is used.^[81]

4.10 Gold Nanoparticles (AuNPs)

Both top-down and bottom-up techniques may be used to create gold nanoparticles. The anisotropies of gold nanoparticles include nanostars, nanorods, nanocages, nanoshells, and nanoprisms. Gold nanoparticles' refractive indices are a number of the most important elements attracting them to healthcare. It allows biomolecules, together with enzymes, carbohydrates, fluorophores, peptides, proteins, and DNA, to attach to gold nanoparticles. This permits molecules to travel more effectively all through the mobile, thereby avoiding any impediments that may arise. The primary use of gold nanoparticles is the accurate imaging of tumor cells. In mixture with optical coherence tomography retailers, the nanoshell can collect 3-dimensional photographs of tissues. In addition to computed tomography, positron emission tomography, and automated tomography analytics, gold nanoparticles have been used.^[82]

5. Drug Loading in Nanocarriers and Release Strategy

Because of the functional organizations on its surface, drug loading and drug launch are powerful. The three

fundamental strategies for effective healing drug loading within the nanocarrier device are covalent bonding conjugation, encapsulation, and electrostatic interaction.

5.1 Covalent Bonding

Drug loading and drug launch are both powerful because of the presence of useful organizations on their surfaces. Covalent bonding conjugation, encapsulation, and electrostatic interaction are the 3 number one mechanisms for powerful therapeutic drug loading inside the nanocarrier system. The nanocarrier-drug aggregate steadily disperses to the cellular membrane, permitting for accurate sustained launch into the goal place. This covalent coupling allows the improvement of a stable nanocarrier technology for handing over unique medications.^[83]

5.2 Encapsulation

Encapsulation is every other approach of incorporating medicinal medications into nanocarrier structures. The concave surface of the nanocarrier permits healing medicinal drug encapsulation. Drugs can be encapsulated with ease within the hollow interiors of polymeric nanocarriers, nanocapsules, dendrimers, and other nanocarriers.^[84] The hydrophobic characteristics of the interior chambers allow for the insertion of extra hydrophobic capsules inside the nanocarrier thru hydrophobic contact or hydrogen bonding. Physical interactions might also produce encapsulation. Liposomes comprise medicines for active or passive topical administration. To release the drug, pH-sensitive neutralization or hydrolysis, thiolysis, and thermolysis techniques are applied.^[84]

5.3 Electrostatic Interactions

The solubility of hydrophobic tablets is progressed by using nanocarriers with practical corporations, which include carboxyl and amine companies. Drug molecules engage electrostatically with the nanocarrier gadget because of their high-density useful groups. Electrostatic touch permits certain nonsteroidal anti-inflammatory medicinal drugs, which includes indomethacin, ciprofloxacin, diflunisal, and ibuprofen, to be simply integrated into the nanocarrier.^[85]

5.4 Active Targeting

The green remedy approach employs a small ligand at the floor of nanocarriers that actively connects to the best receptor, remains inside the goal region, and can be uptaken through unwell cells. This technique is generally used as it has high specificity in bonding the goal spot. The attaching ligand ought to locate protein receptors which can be expanded in sick cells but no longer in healthy ones.^[86] For example, on the surface of C most cancers cells, proteins have elevated. This active focused on enables ill cells to take in extra medication intracellularly. Small molecules, lectins,

antibodies, and their fragments, lipoproteins, peptides (arginyl glycyloaspartic acid), hormones, glycoproteins (transferrin), polysaccharides, low molecular weight vitamins (folic acid), nucleic acids, and boom elements are examples of focused on ligands. Because in their high surface-to-volume ratio, nanocarriers can also be tailor-made to target a wide range of moieties. Active concentrated on surpasses passive focused on as it eliminates the need for off-website online medicine delivery and might reduce multi-drug tolerance.^[23] Internalization or endocytosis with reduced tumor buildup has aroused hobby in lively focused on in cancer treatment due to a couple of ligand–receptor connections. This indicates the presence of receptors present especially in cancer cells.^[84] Receptors consist of the transferrin receptor in breast cancer cells, the epidermal boom element receptor, folate receptors in ovarian or lung most cancers cells, and aptamers. Folate ligands have the gain of being smaller (441 kDa) than antibodies (one hundred sixty, 000 kDa).^[87] The smaller molecule would be absorbed more quickly by way of the target area than via the bigger one. Endothelial cells in the blood–brain barrier own transferrin receptors, Targeting the leaky vasculature of tumor arteries is an alternate method of active targeting mechanisms. This disrupts nutrition and oxygen delivery to the tumor arteries, resulting in tumor cell death.^[88] Vascular cell adhesion molecules, vascular endothelial growth factors, v3 integrins, and matrix metalloproteases may be targeted using active vascular targeting.

Vascular targeting reduces penetration and drug resilience because endothelial cell indicators are more lasting than tumor cell markers. Another method for circumventing the endothelium barrier is the active targeting of caveolar features in endothelial cells.^[89]

5.5 Passive Targeting

Increased bioavailability and retention effect are the primary mechanisms for passive focused on. Cancer causes a leaky vasculature with endothelial mobile diameters many orders of importance (50–70 fold) larger than healthy blood arteries [164]. This induces uneven angiogenesis because of lymphatic drainage and internal vascular improvement. Nanocarriers with greater than forty kDa molecular weights can extravasate thru inflammatory, tumor, or ischemia tissue's leaky vasculature. Passive targeting of this leaky vasculature can also permit the nanocarrier to get thru the endothelial barrier thru the interstitial space, permitting the drug-related nanocarrier to combination at the illness website online. This is referred to as the stepped forward permeability and retention effect, which Matsumura and Maeda found in 1986.^[90] This more desirable bioavailability and retention motion lowers the unfavourable side results due to medicine buildup on the ill web page. The drawback of using low molecular weight tablets to target nanocarriers is they scatter and re-input the

movement. The functional organization's charge and the scale of the nanocarriers govern their aggregation on the target website online. As blood circulation endurance rises, nanocarriers with hydrophilic surfaces and diameters smaller than 200 nm display elevated permeability and retention. As a end result, concentrated on tumor cells based totally on their immunochemical and pathophysiological features compensates for the inadequacies. Even although improved permeability and retention notably have an impact on the focused on of passive malignant cells, they're not found in all most cancers cells. This size-based boom in permeability and retention differs by tumor and affected person.

The excessive fluid pressure in the interstitial area, relative hypoxia, extracellular matrix complexity, endosomal break out, and troubles with tumor infiltration as endothelial gaps trade all effect improved permeability and retention.^[91] As a end result, research of higher bioavailability and retention effects in various tumors are essential for designing nanocarriers with more effectiveness and goal-specific recuperation benefits. DOXILTM, the number one clinically tested passively directed nanocarrier, is doxorubicin in PEGylated liposomes.

6. REMOVAL OF THE RESIDUAL NANOPARTICLE AFTER DRUG RELEASE

Most nanoparticle-drug structures that have been evolved were made of biodegradable substances (ie, phospholipids, lipids, dextran, and chitosan), which permit the discharge of the drug after degradation of the nanoparticle provider. However, nonbiological vendors, along with inorganic nanoparticles, are enormously stable over degrees of temperature and pH and this raises concerns regarding their lack of biodegradation after the drug transport. Hence, if these nonbiological materials are used, they need to have a way of being safely eliminated from the frame or processed and saved in a solid country in the body (ie, inside inactive macrophages). By cautiously controlling the chemistry of the nanoparticles for the duration of their synthesis, nanoplatfoms can also be designed whereby the nanoparticle can disassociate into its basic structural components, which aren't in all likelihood dangerous after drug delivery.

7. NANOPARTICLES AS THERAPEUTIC AGENTS

7.1 Photodynamic Therapy


Photodynamic remedy (PDT) has currently emerged as a possible healing option inside the remedy of cancer. PDT uses a mild-activatable chemical known as a photosensitizer, which absorbs light of a positive wavelength to generate cytotoxic oxygen-primarily based molecular species. These reactive species cause harm to subcellular organelles and plasma membranes, resulting in mobile dying either through apoptosis, necrosis, or autophagy. Photosensitizers are

capable of switch the power they've absorbed from mild to both oxygen molecules to supply singlet oxygen or to surrounding molecules to form loose radicals, that may ultimately react with molecular oxygen to produce superoxide, hydrogen peroxide, and hydroxyl radicals. The effectiveness of PDT depends largely on the efficiency with which photosensitizers can generate singlet oxygen production and their capability to be selectively added at healing concentrations to the goal tumor tissue. One hundred and one As singlet oxygen species have a quick lifespan of less than 3. Five microseconds and may diffuse simplest zero.01 to 0.02 μm , their quantity of damage is constrained to the website online where the photosensitizer molecules gather, which commonly is in the mitochondria or endoplasmic reticulum. Because many photosensitizers take in mild inside the seen spectral place underneath seven-hundred nm, the intensity penetration of light is restrained to just a few millimeters, thereby simplest permitting the treatment of pretty superficial lesions. However, advances in optical engineering have enabled the improvement of optical fibers that may be included into endoscopes, bronchoscopes, and colonoscopes to allow for the delivery of mild to internal frame cavities, thereby extending the scope of PDT. Currently, PDT is being explored within the remedy of numerous cancers along with skin, bladder, prostate, lung, esophageal, pancreatic, belly, a hundred and ten and head and neck cancer to call a few.^[92]

Nanoparticles utilized in PDT can functionally be categorized as both passive or active (Fig. Three). Passive PDT nanoparticles are carriers for photosensitizers and can be crafted from both biodegradable fabric or non-polymer-primarily based substances which include ceramic and steel nanoparticles. Biodegradable nanoparticle companies, crafted from PLGA or PLA, were proven to provide an alternative option to liposomes due to their potential to encapsulate photosensitizers with excessive provider ability. This is important as photosensitizers are fantastically hydrophobic with inherent terrible water solubility, ensuing in aggregation in answer that limits their capacity to be parentally administered. In addition, the morphology and composition of the polymer matrix can be optimized for the managed degradation of the polymer and therefore launch of the photosensitizer molecules. Photosensitizer-loaded nanoparticles were shown to have better photoactivity than "unfastened" photosensitizers. Furthermore, smaller nanoparticle carriers have a extra phototoxic impact as compared with larger carriers because of their better price of intracellular uptake thru endocytosis, resulting inside the release of photosensitizers inside the cytosol and not the extracellular environment. In addition, the smaller the nanoparticle size, the larger the surface vicinity-to-quantity ratio, which increases the floor

area exposed to the surrounding medium, therefore ensuing in higher photosensitizer release prices.^[93]

Nonbiodegradable substances also can be loaded with photosensitizers and have blessings over natural polymeric nanoparticles, consisting of balance; notable manage over length, shape, and porosity; and immunity to adjustments in pH and microbial attack. In addition, they may be without difficulty functionalized for selective targeting of tumor tissue, so one can allow for the selective accumulation of photosensitizers on the website online of cancer at the same time as lowering the buildup of photosensitizers in nontarget normal tissues. This will consequently decrease the awareness of photosensitizers used to generate the same phototoxic impact, thereby increasing the phototherapeutic index. Two photon absorption dyes can convert low-electricity radiation into higher-electricity emissions, which can be directly transferred to molecular oxygen to generate singlet oxygen. The advantage of this machine is that it may be activated in deep tissues by way of mild in the tissue obvious window (750-a thousand nm), which has deeper tissue depth penetration. Nevertheless, the dye's toxicity stays a primary hassle. Entrapping the dye in a nanoparticle provider, that's biologically inert, can therefore reduce its toxicity to normal tissue whilst permitting PDT penetration in deeper tissues. Other agencies also are exploring the usage of thrilling photosensitizers (electricity acceptors) not directly thru fluorescence resonance energy switch from photon soaking up dyes (electricity donors).^[113] By bodily encapsulating the dye and the photosensitizer within the identical nanoparticle, this approach permits for the green transfer of power between the dye, which acts as an intermediary, and the active coencapsulated photosensitizer. For efficient photon excitation the use of this idea, the loading density of the energy-donating photon absorption dye wishes to be much better than that of the strength- accepting photosensitizer. Hence, modified silica nanoparticles had been used as they are biocompatible, solid with out freeing encapsulated hydrophobic molecules, and appropriate for PDT because their porous matrix is permeable to oxygen molecules.^[93]



Nanoparticle

Fig. 3: Nanoparticles in Photodynamic Therapy. Nanoparticles can deliver light-activatable chemicals, known as photosensitizer molecules, to tumor cells for use in photodynamic therapy. After the absorption of light, photosensitizer molecules can generate cytotoxic oxygen-based reactive species, which can subsequently cause cellular damage and cell death via oxidative stress.

Active PDT nanoparticles can themselves generate reactive species without the presence of a photosensitizer. This turned into first appreciated through Samia et al, who located that in addition to sensitizing photosensitizer molecules via a fluorescence resonance energy switch, semiconductor QDs may want to themselves generate singlet oxygen alone thru a triplet energy switch with out the need for photosensitizers, albeit with a decrease performance. A hundred and fifteen Other businesses have additionally investigated the capacity of nanoparticles to play an extra active middleman role inside the procedure of PDT, in addition to encapsulating photosensitizers and concentrated on them to cancer cells.^[94] These nanoparticles will emit luminance of the precise wavelength to lively photosensitizers after irradiation with x-rays, thereby supplying remedy to regions deep inside the body that may be reached with ionizing radiation. Similarly, upconverting nanoparticles are able to take low-electricity radiation (ie, near-infrared radiation [NIR], that could penetrate tissue depth of approximately an order of importance greater than seen light) and generate higher-power light which could spark off photosensitizers to produce singlet oxygen from dissolved molecular oxygen within the microenvironment. This is carried out following the simultaneous absorption of 2 low-power photons, permitting the nanoparticle to transition from a ground to an excited country through using a transition metal or an extraordinary earth ion consisting of lanthanide. Quantum mechanically, this takes region thru a virtual intermediate state following the absorption of the first photon.^[94]

7.2 Gene Silencing

Gene therapy includes the use of plasmid DNA, antisense oligonucleotides, or small interfering RNA (siRNA), the latter of which requires the lowest dose for gene regulation. siRNA is formed from the cleavage of double-stranded RNA by using “dicer,” that is an ribonuclease (RNase) III endonuclease.

SiRNAs are quick double-stranded RNA fragments measuring about 20 to 25 nucleotides in length and have the potential to interfere with the interpretation of specific mRNAs complimentary to its nucleotide collection. siRNAs interact with a multifunctional protein referred to as Argonaute, which is the catalytic thing of the RNA-prompted silencing complex. Here, duplex siRNA is unwound and Argonaute degrades the passenger RNA strand, thereby permitting the closing template/antisense strand to bind a complementary mRNA. Argonaute then cleaves the mRNA via its endonuclease hobby, leading to silencing of gene expression, otherwise called RNA interference (RNAi).^[95] This impact can also remaining for 3 to 7 days in hastily dividing cells or for lots weeks in nondividing cells.

As the mechanisms underlying cancer grow to be higher defined, multiple molecular targets are being diagnosed. SiRNA consequently holds first-rate promise in being capable of silence now not only one but several genes that make contributions to most cancers progression with excessive efficacy and specificity, thereby permitting the simultaneous targeting of multiple pathways. Several in vitro and in vivo studies have investigated RNAi in pathways that power most cancers, along with apoptosis, cell cycle law, mobile senescence, and tumor-host interactions, with promising effects^[96], one hundred twenty However, there are several limitations that have been highlighted by Miele et al that reduce the healing efficacy of siRNA, such as 1) delivery issues, 2) aspect results because of off-target movements (ie, partial pairing of siRNA with the complimentary series from unintended nontarget mRNA transcripts), 3) disturbance of physiological capabilities of the cell machinery concerned in gene silencing, and 4) the induction of the innate immune reaction mediated through kind 1 interferon and proinflammatory cytokines.^[96]




Fig. 4: Precursor mRNA (pmRNA). Nanoparticles in RNA Interference Gene Therapy. Nanoparticles can deliver small interfering RNAs (siRNAs) into tumor cells, where they can interfere with the translation of specific messenger RNA (mRNA) molecules. siRNA interacts with a multifunctional protein called Argonaute, which is the catalytic component of the RNA-induced silencing complex (RISC). Here, duplex siRNA is unwound and Argonaute degrades the passenger RNA strand, thereby allowing the remaining template/antisense strand to bind to a complementary mRNA. Argonaute then cleaves the mRNA through its endonuclease activity, leading to silencing of gene expression, otherwise known as RNA interference. pmRNA indicates precursor mRNA.

All the siRNA-nanoparticle shipping structures being developed, nanoliposomes are likely the nearest to being clinically translated. Nanoliposomes are made from organic cloth and consist of a phospholipid bilayer and an aqueous core which can keep and engage with siRNA thru complexes which can be stabilized with the aid of electrostatic interactions. They are normally impartial in fee and approximately 30 to forty nm in size, thereby enabling their efficient uptake into cells. Nanoliposomes guard siRNA within the circulation from endonuclease interest; but, their brief 1/2 -lifestyles in serum and fast clearance from the circulation by using the RES (ie, the liver, spleen, lung, and bone marrow) restrict their use as remedy and could require a continuous infusion or common administration. Several agencies are presently investigating the capacity use of sustained-release polymer formulations to triumph over this trouble. Solid lipid nanoparticles are also being investigated as they're organized from physiological lipids and consequently have great biocompatibility and minimum organic toxicity.^[97]

Nonbiological or synthetic nanoparticles, such as inorganic crystals and noble metals, have additionally been explored as gene transport vehicles due to their multiplied stability and potential to be easily functionalized with oligonucleotides. The most excellent size of synthetic nanoparticle companies appears to lie among five and a hundred nm because nanoparticles measuring less than five nm undergo rapid renal clearance while the ones measuring greater than 100 nm are taken up by means of the RES, where they're degraded by way of activated monocytes and macrophages. Furthermore, particles measuring extra

than two hundred nm set off the supplement machine and are consequently cleared greater correctly and swiftly than smaller nanoparticles. Incorporation of siRNA into gold nanoparticles became first accomplished by means of Oishi et al with more recent advances the usage of a layer-via-layer assembly to create supramolecular structures to permit for the sustained launch of siRNA. One hundred twenty five However, as chemical amendment of both the service floor and the transported drug is required, new delivery techniques primarily based on porous silicon are being advanced.^[98]

In 2010, Davis et al undertook the first evidence-of-precept observe wherein siRNA designed to lessen expression of the M2 subunit of ribonucleotide reductase (RRM2) turned into packaged right into a nanoparticle containing a linear cyclodextrin-primarily based polymer, a human transferrin protein to engage transferrin receptors on the surface of the cancer cells, and PEG to promote nanoparticle stability. In a small section 1 medical trial, these nanoparticles filled with siRNA centered towards RRM2 have been administered systemically on days 1, 3, 8, and 10 every 21 days through a 30 -minute intravenous infusion to sufferers with cancer that turned into refractory to the same old of care. Tumor biopsies in a confined wide variety of patients following treatment confirmed nanoparticles inside the intracellular compartment with corresponding reductions in each RRM2 mRNA and protein degrees, demonstrating that siRNA systemically administered to people can produce a selected gene inhibition via an RNAi mechanism. However, little continues to be known about the pharmacodynamics of the RNAi outcomes,

which depend on a combination of nanoparticle disassembly time and the time that the siRNA is living in the RNAi equipment. Several other early scientific trials are currently underway investigating using siRNA in persistent myeloid leukemia, liver tumors, neuroblastoma, and advanced solid malignancies.^[96]

7.3 Photothermal Therapy

Hyperthermia refers to temperatures between forty°C and forty five°C. Temperatures extra than forty two°C have been shown to make cancer cells extra liable to the consequences of extra remedies which include irradiation, further to inflicting a diploma of apoptosis, at the same time as temperatures above 45°C can motive direct cell loss of life (ie, thermoablation). Hyperthermic remedy of tumors entails heating tumors using radiofrequency (RF), microwaves, magnetic fields, or ultrasound to purpose irreversible cell damage by way of loosening membranes and denaturing proteins, which in the end effects in mobile demise. Although this effect is greater selective for tumors because of their reduced warmness tolerance, thermal therapy has been restrained with the aid of damage brought about to surrounding regular tissue. Photothermal remedy (PTT) ambitions to conquer this hassle through the use of photothermal dealers to reap extra controlled and selective heating of the target vicinity, thereby confining thermal damage to the tumor.^[99]

For photothermal dealers to be effective, they want to have an better light absorption and efficient mild- to-warmness conversions.¹²⁹ Traditional marketers consist of natural chromophores, which suffer from low absorption, or external dyes (ie, indocyanine inexperienced), which be afflicted by photobleaching. However, the improvement of noble metallic nanoparticles (ie, gold nanospheres, nanorods, nanoshells, and nanocages) and carbon nanotubes has overcome those problems as they've strong absorption inside the NIR areas of the electromagnetic spectrum, in particular at 650 to 900 nm, because of floor plasmon resonance (SPR). A hundred thirty This is wonderful as most organic tissues show off minimal mild absorption on this range, thereby allowing for elevated intensity penetration of light. Generally, spherical gold nanoparticles have their maximal SPR

absorption peak within the seen spectrum, around 520 nm, without much tunability of this top. In assessment, gold nanorods have 2 absorption bands alongside every course of the rod (ie, the longitudinal and transverse axes), with the transverse plasmon band displaying a sturdy absorption height at about 520 nm and the longitudinal plasmon band located at better frequency, which may be tuned inside the NIR region depending on their length-to-width ratio, thereby making them appealing for in vivo PTT. Similarly, the SPR absorption top for gold nanoshells can be tuned by using altering their shell thickness-to-core radius ratio. A hundred thirty,^[131] Due to the SPR of nanoparticles, their absorption coefficients are four to 5 orders of value better than those presented by way of photothermal dyes. Photoexcitation of metal nanoparticles with light frequencies that overlap with the nanoparticle SPR absorption band results in the formation of a heated electron gas that subsequently cools rapidly within approximately 1 picosecond (ps) by exchanging energy with the nanoparticle lattice. The lattice then cools by exchanging heat with the surrounding environment within approximately 100 ps to cause localized tissue destruction.^[133] In addition to the mechanisms of heat- induced cellular destruction described above, the heating of gold nanoparticles also causes cavitation bubble formation around the nanoparticle, which in turn results in mechanical stress leading to cell damage.^[100]

Studies have shown that nanoparticles normally have a higher light-to-heat conversion as compared with traditional dyes, thereby requiring lower laser energies to attain neighborhood cellular destruction. To increase the efficiency of the light-to-warmth conversion, nanoparticles are required to be inside the length range of tens to hundreds of nm; but, this outcomes of their poor clearance and accumulation in the RES. Hence, studies are presently looking at the usage of smaller noble metal nanoparticles which can avoid the RES but that aggregate on the site of the tumor via self-meeting. The loading of nanoparticles on tumor cells will increase the optical density thereby ensuing in decrease laser powers required to raise the temperature above the edge needed for mobile destruction.




Fig:-5: Nanoparticles in Photothermal Therapy. Nanoparticles can be used in photothermal therapy to cause localized destruction of tumors after absorption of light due to their efficient light-to-heat conversion. The

controlled and selective heating of nanoparticles allows thermal damage to be confined to the tumor while minimizing any damage to surrounding normal tissue.

Iron oxide nanoparticles in water have additionally been shown to generate heat whilst injected without delay into tumors within the presence of an externally implemented oscillating magnetic subject.^[136] As iron nanoparticles inside water (ie, magnetic fluids) have a high particle density in keeping with quantity ensuing in a massive normal floor area of magnetic factors, this effects in terrific strength absorption competencies making them eminently suitable for contactless, selective interstitial heating of tumors.^[137]

In fashions of prostate most cancers, 138 malignant glioma,^[139] and breast cancer, a hundred and forty magnetic fluid hyperthermia has shown promising results with section 1 scientific trials for prostate most cancers and phase 2 scientific trials for brain cancer which are presently underway.¹²⁶ At present, magnetic fluid hyperthermia cannot be accomplished with systemic injection of iron oxide nanoparticles.^[101]

8. Nanoparticles as Imaging Agents

Conventional imaging using simple radiographs, ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) has historically been utilized in each most cancers screening and follow-up. However, these kind of modalities depend upon detecting most cancers once it turns into a visible bodily entity, at round 1 cm,³ at which factor the tumor mass will already contain about 1 billion most cancers cells. Over the past decade, there has therefore been a paradigm shift from anatomical imaging, which detects macroscopic/gross pathology, to molecular imaging, which has the ability to detect cancer a whole lot earlier on the molecular degree,

lengthy before phenotypic changes arise. Molecular imaging permits the genetic modifications worried in oncogenesis to be characterized in vivo, thereby predicting the form of molecular therapy in an effort to show maximum useful for the affected person (ie, personalized remedy). It also permits the repeated noninvasive monitoring of the ailment for reaction, development, and transformation following therapy or recurrence.^[102]

While conventional imaging modalities have the option of using imaging marketers to focus on current functions (ie, blood vessels and tissue perfusion following intravenous comparison medium), molecular imaging strategies must use imaging sellers. Traditionally, small molecules, which degree about less than 2000 daltons and approximately 1 nm, have routinely been used as imaging agents in clinical practice (ie, 2-deoxy-2-(18F)fluoro-D-glucose [FDG] for positron emission tomography [PET], iodinated small molecules for CT, and chelated gadolinium for MRI). However, their low signal depth, bad stability, nonspecific interactions, and rapid clearance from the move have caused the development of newer probes. Nanoparticles have proven wonderful promise in overcoming these limitations and are presently being advanced as molecular imaging agents (Table 2). example, whilst the use of optical imaging modalities, nanoparticles can boom signal depth, thereby allowing fewer numbers of cells to be imaged at extra tissue depths, in addition to presenting imaging signals which might be solid over longer intervals of time.^[103]

Table 3: Examples of Nanoparticles Used in Cancer Imaging.

IMAGING MODALITY	DESCRIPTION OF NANOPARTICLE	CANCER IMAGED BY THE NANOPARTICLE	STAGE OF DEVELOPMENT/CLINICAL TRIAL NO.
MRI	Superparamagnetic iron oxide nanoparticles	Liver tumors (ie, hepatocellular carcinoma, liver metastases)	Currently used in clinical practice ^[142]
		High-grade glioma	NCT00769093
	Ultrasmall superparamagnetic iron oxide nanoparticle	Preoperative staging of pancreatic cancer	NCT00920023
		Pelvic lymph node metastases from prostate, bladder, or other GU cancers	NCT00147238
CT	Heavy metal (ie, gold, lanthanide, and tantalum) nanoparticles	Solid organ tumors	Preclinical stage of development ^[143]
SPECT	TC-99m sulfur colloid nanoparticles	Sentinel lymph node mapping in invasive breast cancer	NCT00438477

Nanoparticles also have a excessive avidity as they can be covered with a couple of copies of ligands, on the way to permit multiple bond interactions with cellular target moieties, thereby growing their association

consistent by using four to 5 orders of value. This is high-quality because it will permit more nanoparticles to accumulate on the web page of the tumor, thereby growing the signal-to-noise ratio, which permits

cancerous tissue to be higher highlighted relative to adjacent everyday tissue. Most nanoparticle imaging retailers also are larger than 10 nm and are consequently not generally cleared renally from the circulation; this permits them to have longer move times whilst as compared with small molecules (ie, days vs mins). That is useful because it lets in repeated imaging without the want for similarly nanoparticle administration. Interestingly, research have additionally proven that smaller nanoparticles have a more uniform tissue biodistribution and that nonspherical nanoparticles (ie, nanodisks, nanotubes, nanoworms, and many others) are extra correctly delivered to target regions while in comparison with round nanoparticles.^[104]

However, this must be balanced against the probably extended toxicity that is associated with nonspherical nanoparticles. As most cancers is hardly ever resulting from a single molecular alteration, simultaneously detecting more than one molecular objectives which are upregulated all through oncogenesis (ie, a phenomenon referred to as multiplexing) will boom the specificity of cancer detection. One way to do this is to label different nanoparticles, every in opposition to a unmarried molecular biomarker target, and then administer a lot of these nanoparticles straight away. The signals detected from the one of a kind nanoparticles bound to the cancer cells can then be decoded to allow a molecular profile of the cancer to be decided. In turn, this could enable a molecularly targeted remedy to be designed and administered to the affected person. An alternative approach if the molecular profile of the cancer is already known is to label a unmarried nanoparticle with multiple unique ligands, each directed at a different molecular goal recognise to be upregulated with the aid of the tumor being investigated. As the tumor will include extra of these targets compared with heritage tissue, it's going to bind greater nanoparticles thereby producing a more potent sign. Finally, nanoparticles are able to be designed to be multimodal such that they can be imaged by 2 or extra special imaging modalities (eg, fluorescence and MRI). To growth the shipping efficiency of nanoparticle imaging dealers to the tumor bed, numerous companies also are currently discovering methods of personally injecting the subcomponents or constructing blocks of a nanoparticle. In the presence of positive triggers consisting of pH adjustment, discount, or enzyme cleavage, those subcomponents are then capable of self-gather to create a supramolecular nanoparticle probe that can then be used for imaging. The gain of this technique is that the person subcomponents could be smaller and as a result have better get entry to to the tumor thereby maximizing accumulation on the target site. Examples encompass gadolinium-containing monomers that collect in cells thru thiol-sensitive discount of 1,2-aminothiol and a pair of-cyanobenzothiazole and probes with a motif touchy to

proteases along with furin and caspase-three, which are overexpressed in tumor cells.^[105]

Although lots of work is currently being undertaken preclinically to expand new nanoparticle retailers, superparamagnetic iron oxide nanoparticles (SPIONs) are already being used in medical exercise for hepatic, cardiovascular, cellular, and lymphatic imaging. Iron oxide (magnetite, Fe₃O₄; maghemite, Fe₂O₃) nanoparticles turn out to be superparamagnetic at room temperature if their center diameter is 20 nm or much less, which lets in for susceptibility consequences at micromolar concentrations that modify the T₂ and T₂* rest times of water protons for superior MRI comparison. One hundred fifty five SPIONs are also considered to have low toxicity in vivo as they may be notion to be biodegradable, with the iron from the nanoparticles launched upon degradation into the everyday plasma iron pool, where it can finally be incorporated into hemoglobin in erythrocytes or used for different metabolic methods. SPIONs were used to characterize liver lesions on the grounds that they're phagocytosed by way of cells of the RES. As everyday liver parenchyma consists of RES, they will collect SPIONs, ensuing in a lower in sign intensity on both T₂-weighted and T₁-weighted pictures. In evaluation, most liver tumors do not contain RES and consequently they will now not uptake SPIONs, thereby enhancing evaluation between the tumor (excessive sign) and the surrounding tissue (low sign).¹⁵⁸ However, these sign characteristics are reversed while SPIONs are combined with ligands for lively focused on. ¹⁵⁹ In these situations, SPIONs will now gather on the web site of the tumor, resulting in a low sign as compared with the historical past liver parenchyma; however, this relies on SPIONs avoiding the RES. To avoid the RES and improve colloidal balance and biocompatibility, SPIONs used for energetic concentrated on are commonly coated with a polymer (ie, dextran, starch, or PEG).¹⁵⁹ Ligands along with folate are then conjugated to SPIONs via their polymer coatings of both dextran or PEG. Folate has been used as a ligand due to the fact folate receptors are expressed in restrained portions on the apical surfaces of regular epithelial cells but are generally overexpressed in cancerous tissues due to the crucial role that folate performs in cell proliferation. Transferrin has additionally been covalently coupled to SPIONs as it will bind to the transferrin receptor (additionally referred to as CD71), that is a type II transmembrane glycoprotein that is overexpressed at the surfaces of proliferating most cancers cells due to their improved iron requirements. SPIONs have additionally been mixed with peptide sequences which includes arginyl-glycyl-aspartic acid (RGD), that can combine with integrins including $\alpha\beta3$ which are expressed at the floor of proliferating endothelial cells including those undergoing angiogenesis. Initially, SPIONs conjugated with monoclonal antibodies were now not taken into

consideration sensible for *in vivo* diagnostics due to the big particle length, which facilitated their rapid clearance via the RES. However, this has proved not to be the case, with several research showing monoclonal antibody-conjugated SPIONs having strong specificity for antigen-expressing tissues. Antibodies towards EGFR were conjugated with SPIONs for the detection of colorectal, small cellular lung, and esophageal squamous mobile carcinomas in experimental models. Nevertheless, the greatly improved size of the nanoparticle-antibody complex does bring about decreased stealth-like characteristics. Hence, a few groups are actually conjugating SPIONs with aptamers, that are artificial, very small, selected oligonucleotide sequences that may bind ligands with very excessive specificity and affinity. There are also twin-modality probes being developed along with dextran-coated 64Cu-SPIONs, which clinicians are hoping to use for dual-mode MRI/PET imaging in the near destiny.^[106]

Optical imaging has in no way reached its complete capacity in medical practice and, for the maximum component, stays a preclinical/studies imaging modality. Traditionally, optical imaging has trusted fluorescence however its *in vivo* applications have been restricted through 1) the small number of fluorescent imaging marketers available inside the NIR spectrum, which limits the usage of low-electricity lasers to interrogate specimens; 2) high background autofluorescence from superficial tissues, which restricts the sensitivity and depth of this imaging modality; three) the massive spectral overlap between fluorescent imaging retailers, which prevents the detection of multiple targets simultaneously; and the speedy photobleaching of fluorescent molecules, which limits take a look at length. A new

magnificence of nanoparticle that uses optical imaging is QDs. These are semiconductor nanocrystals usually crafted from selenides or sulfides of metals which include cadmium or zinc and range in length from 2 to 10 nm. The wavelength of the emitted mild does no longer depend upon the cloth of the QD, but instead its bodily size. Hence, the potential to exactly manipulate, or music, the size of the QD determines the wavelength and colour of the emitted light, in any other case called the “size quantization impact.” The QD emission profile can therefore be tuned to comprise feature peaks at wavelengths across the visible spectrum impartial of the excitation wavelength so as for the emitted mild to be perceived by way of the human eye. QDs have additionally been proven to be about 20 instances brighter and a hundred instances more solid (ie, much less liable to photobleaching) than conventional fluorescent newshounds, which lets in them to have extra tissue penetration even as additionally being more sensible for lengthy-time period imaging. To date, QDs have been used in a lot of molecular biology packages including DNA detection, cell sorting and tracking, and focused on molecular markers *in vivo*. A hundred seventy five Indeed, QDs had been bioconjugated with several ligands, inclusive of with prostate-unique membrane antigen, EGFR, folate, and RGD peptides to name a few. Multimodality QDs are also being developed inclusive of twin-function PET–close to-infrared fluorescence (NIRF) QDs labeled with RDG peptides. While the NIRF sign allows deeper tissue penetrance with fluorescence emissions beyond the spectral range of the sign produced by means of blood and tissues (ie, autofluorescence), thereby resulting in a excessive sign-to-background noise ratio, the PET sign lets in fantastically quantitative tomographic imaging to be finished.^[107]




Fig. 6: Raman Nanoparticles Used in Image Multiplexing. (A) An example of a spectral intensity map from Raman nanoparticles targeting a tumor in a xenograft mouse model. (B) A schematic representation of a Raman nanoparticle. After activation of the Raman molecular layer with a laser light of a specific wavelength, the

Raman nanoparticle emits a Raman signal/spectral trace that can be subsequently detected. (C) An example of 4 individual Raman spectral traces as a result of different Raman molecular layers in 4 different Raman nanoparticles.




Fig. 7: Multimodal Nanoparticles. Nanoparticles can be designed to be detected by more than one imaging modality (ie, magnetic resonance imaging [MRI], photoacoustic imaging, and Raman spectroscopy). When injected intravenously into mice with brain tumors, new triple-modality nanoparticles can accumulate within the tumor due to disruption in the blood-brain barrier. Preoperatively, their gadolinium (Gd) coating allows for their detection and hence tumor localization with MRI. During surgery, their Raman molecular layer guides fine tumor resection with Raman spectroscopy while their high optical absorbance coefficient allows photoacoustic imaging to guide deep tumor localization. After surgery, tissue specimens can be analyzed ex vivo using Raman spectroscopy to confirm tumor- free/clean resection margins. MPR indicates magnetic resonance-photoacoustic-Raman imaging.

Nanoparticles have additionally been substantially advanced for photoacoustic imaging, which is a unique nonionizing imaging modality that synergizes optical and ultrasound imaging. In this approach, nanosecond pulses of infrared light are absorbed and converted into kinetic energy and localized heating, which in flip releases a stress or RF wave that can be detected and translated into a real-time picture in a comparable fashion to ultrasound. Optical absorption may be either related to endogenous molecules (ie, hemoglobin) or executed through externally administered molecules inclusive of nanoparticles (ie, nanoclusters, SPIONs, gold nanoparticles, and unmarried-walled carbon nanotubes [SWCNTs]). Nanoparticle imaging sellers had been verified to supply more photoacoustic signaling than small molecules on a mole-to-mole foundation Although gold nanoparticles had been initially preferred due to their excessive absorption characteristics and capacity

to govern their spectra (allowing for multiplexing), their surprisingly big length consequences in rapid clearance from the stream thru the RES. Nonetheless, experimental studies the usage of gold and copper nanoparticles have shown promising consequences with photoacoustic imaging for identifying sentinel lymph nodes whilst imaging the axilla for lymph node metastases from breast most cancers. However, the improvement of SWCNTs as a photoacoustic imaging agent has end up of exceptional hobby due to their precise high element ratio (about 1:100) and high floor place-to-volume ratio. These attributes reduce their uptake by way of the RES whilst having an improved affinity for molecular targets because of their multivalency consequences.¹⁹⁴ Indeed, SWCNTs had been conjugated with RGD peptides and used as a assessment agent for noninvasive photoacoustic imaging of tumor vasculature. One hundred ninety In addition, the excessive photoacoustic sign from

SWCNTs permits for excessive-decision, 3-d photoacoustic photographs with good sized depth of penetration, unique depth information, and submillimeter decision at nanomolar sensitivity, features which have not but been achieved by using other molecular imaging modalities. Newer research are also analyzing magnetoacoustic imaging as a variation of photoacoustic imaging, in which MRI is used in preference to infrared mild to stimulate SPIONs at extra depths to create an ultrasound image.^[108]

9. Challenges Ahead

Although noncarriers constitute a unique and dependable approach to turning in anticancer pills, several challenges ought to be addressed. Non-particular sequestration (internalization and binding to the surface of scavenger cells) of nanocarriers by the reticuloendothelial gadget (RES), for instance, is one of the essential hurdles to the scientific translation of systemically administered nanocarriers because it impedes the delivery of an ideal dose to the goal site (ailment tissues) and might raise toxicity concerns. To conquer this unintended RES accumulation, diverse RES blockade strategies had been developed. The fast elimination of nanoparticles from the bloodstream by the mononuclear phagocyte machine limits the pastime of many nanoparticle formulations. The temporary and partial blocking off of the mononuclear phagocyte gadget may decorate the performance of a extensive sort of nanoparticle capsules. Moreover, one of the primary important barriers going through the systemic administration of nano-based medicines is their non-unique clearance by the liver, which may lower the transport performance of these tablets to the target organ.^[109]

10. Future Directions

- Numerous research and medical trials using polymeric nanoparticles in cancer therapy suggest that combining polymeric nanoparticle-primarily based methodologies in most cancers therapy can be a unique and destiny method, resulting in more efficacy and drug concentrated on with decreased toxicity.^[52]
- The future of anticancer therapy would require combining present techniques. Therefore, it's far critical to understand which techniques carry out efficaciously whilst combined to gain the maximum significant anticancer effect. Optimal cancer aggregate remedy can be devised via comprehending the proper mechanisms by way of which medicinal drugs eradicate tumors. Nanoparticles were the maximum promising anticancer approach thus far.
- New measures for the development of composite aggregate remedy have to be evolved, necessitating expanded studies on the diverse classes of aggregate remedies, our cognizance of inter-drug connections in some instances, the

spatiotemporal launch of anticancer marketers, vague initiation of the innate immune reaction by such composite fusion nanomedicine, variability of metastatic foci, diversification of organ surroundings, and provision of bioactive composites.

- Such healing procedures need to be created by incorporating scientific research containing a sufficient number of sufferers with without a doubt equal biomarker expression and by way of developing more effective pre-clinical fashions. Future cancer nanomedicine and nanotechnology combination immunotherapy with mechanistically practical healing combos is meant to boost “multi-centered therapy” with the aid of interfering with chemoresistance and growing the impact of therapeutic configurations.
- Incorporating proteomics records from medical samples, composite nanotherapy, and immunoncology could also expand fairly effective and unique nanomedicine.
- In addition, in vitro models, and in vivo pharmacokinetic profiles must be superior to increase the cancer therapeutic efficacy of modern medicines and new drug delivery structures.

CONCLUSION

This evaluation has verified many one-of-a-kind applications for which nanoparticles are getting used within the combat in opposition to cancer. Their particular attributes have allowed clinicians to provide them both as new remedies (monotherapy) or as adjuncts to present treatments (blended remedy) to improve healing effectiveness. Although a few nanoparticles have now not been a success while being clinically translated, numerous new and promising nanoparticles are currently in development and display notable promise, thereby supplying hope for new treatment alternatives inside the close to future. However, all newly developed nanoparticles, whether or not they're used as carriers for tablets, therapeutic marketers, or imaging sellers, will need to be thoroughly characterised physiochemically, pharmacologically, and immunologically before they may be authorised to be used in people. The distribution of nanoparticle length, uniformity, and consistency among batches also needs to be tightly regulated. Furthermore, for nanoparticles containing polymer layers and ligands, the loading density have to be decided (ie, by using using electron microscopy, electron dispersion spectroscopy, absorption spectroscopy, and so on). Nanoparticles had been shown to possess very distinctive homes compared with their corresponding bulk fabric, which has widespread implications for their use in vivo due to the fact that their small length will affect their mode of endocytosis, mobile trafficking, and processing. In addition, their excessive floor area-to-volume ratio, floor reactivity and price will dramatically modify their chemical and physical houses, resulting in them

possessing surprising toxicities and biological interactions. Although numerous studies have investigated the toxicity related to unique nanoparticles, the consequences are notably variable, Which can be attributed, in part, to the specific shapes, sizes, and chemical preparations of nanoparticles in addition to the sort of human cell line studied. Hence, brief- time period and long-time period toxicity research may even want to be undertaken in both cellular way of life and living animal fashions earlier than they are able to gain FDA popularity of scientific trials. Nevertheless, with our endured force to cure most cancers and our dedication to apprehend the molecular mechanisms that power this disease to permit its early detection, nanotechnology presents hope in developing new methods to diagnose, treat, and follow sufferers with most cancers in the 21st century.

BIBLIOGRAPHY

1. *Mechanisms of Multidrug Resistance in Cancer Chemotherapy*. Karol Bukowski 1, *, Mateusz Kciuk 1, Renata Kontek 1. PubMed.
2. Malik D., Mahendiratta S., Kaur H., Medhi B. **Futuristic**. <https://www.sciencedirect.com/science/article/abs/pii/S0378111921005011?via%3Dihub>. <https://pubmed.ncbi.nlm.nih.gov/34411650/>. [Online]
3. J. Jeevanandam, A. Barhoum, Y.S. Chan, A. Dufresne, M.K. Danquah. <https://www.sciencedirect.com/science/article/pii/S0378517324005799#b0290>. <https://www.sciencedirect.com/science/article/pii/S0378517324005799#b0290>. [Online]
4. D. Luo, K.A. Carter, J.F. Lovell. Nanomedical engineering: shaping future nanomedicines. [Online] <https://wires.onlinelibrary.wiley.com/doi/10.1002/wnan.1315>.
5. T., Lancet. [DOI] [PubMed] [Google Scholar]. *GLOBOCAN: counting the toll of cancer*. *Lancet (London, England)*, 2018; 392(10152): 985. [Online] <https://pubmed.ncbi.nlm.nih.gov/30264708/>.
6. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. [in:] *Nano-enabled medical applications*. Jenny Stanford Publ.: 61–91. [DOI] [PubMed] [Google Scholar]. [Online] https://scholar.google.com/scholar_lookup?title=Nano-enabled%20medical%20applications&publication_year=2020&.
7. Ghazal, Huma. PlumX Metrics . *Role of nanoparticles in enhancing chemotherapy efficacy for cancer treatment*. [Online] <https://doi.org/10.1016/j.nxmate.2024.100128>.
8. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumorotropic accumulation of proteins and the antitumor agent smancs. *Cancer Res.*, 1986; 46: 6387–6392. [PubMed] [Google Scholar][Ref list]. [Online] <https://pubmed.ncbi.nlm.nih.gov/2946403/>.
9. Snyder I.S.A.S., Janet L. Anticancer Drug. [(accessed on 5 July 2022)]; *Encycl. Br.* 2018 Available online. [Online] <https://www.britannica.com/science/anticancer-drug>.
10. Espinosa E., Zamora P., Feliu J., Barón M.G. [DOI] [PubMed] [Google Scholar]. [Online] <https://pubmed.ncbi.nlm.nih.gov/14585261/>.
11. Gotink K.J., Verheul H.M.W. Anti-angiogenic tyrosine kinase inhibitors: What is their mechanism of action? *Angiogenesis*. doi: 10.1007/s10456-009-9160-6. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online] <https://pubmed.ncbi.nlm.nih.gov/20012482/>.
12. Qin S., Li A., Yi M., Yu S., Zhang M., Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. *J. Hematol. Oncol.* doi: 10.1186/s13045-019-0718-5. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online] <https://pubmed.ncbi.nlm.nih.gov/30866992/>.
13. Li J., Dirisala A., Ge Z., Wang Y., Yin W., Ke W., Toh K., Xie J., Matsumoto Y., Anraku Y., et al. Therapeutic Vesicular Nanoreactors with Tumor-Specific Activation and Self-Destruction for Synergistic Tumor Ablation. *Angew. Chem. Int. Ed.*, 2017; 56: 14025–14030. doi: 10.1002/anie.201706964. [DOI] [PubMed] [Google Scholar]. [Online] <https://onlinelibrary.wiley.com/doi/10.1002/anie.201706964>.
14. Wang D., Shen M., Kitamura N., Sennari Y., Morita K., Tsukada J., Kanazawa T., Yoshida Y. Mitogen- activated protein kinases are involved in cucurbitacin D-induced antitumor effects on adult T-cell leukemia cells. *Investig. New Drugs.*, 2020; 39: 122–130. doi: 10.1007/s10637-020-00997-0. [DOI] [PubMed] [Google Scholar]. [Online] <https://link.springer.com/article/10.1007/s10637-020-00997-0>.
15. García-Reyes B., Kretz A.-L., Ruff J.-P., von Karstedt S., Hillenbrand A., Knippschild U., Henne-Bruns D., Lemke J. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. *Int. J. Mol. Sci.*, 2018; 19: 3219. doi: 10.3390/ijms19103219. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online] <https://pmc.ncbi.nlm.nih.gov/articles/PMC6214075/>.
16. Schmitz M.L., Kracht M. Cyclin-Dependent Kinases as Coregulators of Inflammatory Gene Expression. . *Trends Pharmacol. Sci.*, 2016; 37: 101–113. doi: 10.1016/j.tips.2015.10.004. [DOI] [PubMed] [Google Scholar]. [Online] [https://www.cell.com/trends/pharmacological-sciences/abstract/S0165-6147\(15\)00223-0?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0165614715002230](https://www.cell.com/trends/pharmacological-sciences/abstract/S0165-6147(15)00223-0?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0165614715002230).

17. **Roskoski R., Jr.** Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. *Pharmacol. Res.*, 2018; 139: 471–488. doi: 10.1016/j.phrs.2018.11.035. [DOI] [PubMed] [Google Scholar]. [Online] <https://www.sciencedirect.com/science/article/abs/pii/S1043661818318784?via%3Dihub>.
18. **Wang B., Chu D.** Dihydropyridophthalazinone Inhibitors of Poly (adp-ribose) Polymerase. (*parp*) 8420650B2. *Google U.S. Patent. 2010 February 11*; [Online]
19. **Gyori D., Chessa T., Hawkins P.T., Stephens L.R.** Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment. *Cancers.*, 2017; 9: 24. doi: 10.3390/cancers9030024. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online] <https://pmc.ncbi.nlm.nih.gov/articles/PMC5366819/>.
20. **Sabbah D., Hu J., Zhong H.A.** Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors. *Curr. Top. Med. Chem.*, 2016; 16: 1413–1426. doi: 10.2174/1568026615666150915115823. [DOI] [PubMed] [Google Scholar]. [Online] <https://www.eurekaselect.com/article/70402>.
21. **Wong Y.N.S., Ferraldeschi R., Attard G., de Bono.** Evolution of androgen receptor targeted therapy for advanced prostate cancer. *Nat. Rev. Clin. Oncol.*, 2014; 11: 365–376. doi: 10.1038/nrclinonc.2014.72. [DOI] [PubMed] [Google Scholar]. [Online] <https://www.nature.com/articles/nrclinonc.2014.72>.
22. **Fujita K., Nonomura N.** Role of Androgen Receptor in Prostate Cancer: A Review. *World J. Men's Health*, 2019; 37: 288–295. doi: 10.5534/wjmh.180040. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online] <https://wjmh.org/DOIx.php?id=10.5534/wjmh.180040>.
23. **Sun L.-C., Coy D.H.** Somatostatin receptor-targeted anti-cancer therapy. *Curr. Drug Deliv.*, 2011; 8: 2–10. doi: 10.2174/156720111793663633. [DOI] [PubMed] [Google Scholar]. [Online] 2011. <https://pubmed.ncbi.nlm.nih.gov/21034425/>.
24. **E., Terpos.** The synergistic effect of panobinostat (LBH589) with melphalan or doxorubicin on multiple myeloma cells; rationale for the use of combination regimens in myeloma patients, 2011; 35: 295–296. doi: 10.1016/j.leukres.2010.10.019. [DOI] [PubMed] [Google Scholar]. [Online] <https://www.sciencedirect.com/science/article/abs/pii/S0145212610005126?via%3Dihub>.
25. **Ropero S., Esteller M.** The role of histone deacetylases (HDACs) in human cancer. *Mol. Oncol.* [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2007; 1: 19–25. <https://febs.onlinelibrary.wiley.com/doi/10.1016/j.molonc.2007.01.001>.
26. **Malogolovkin A., Gasanov N., Egorov A., Weener M., Ivanov R., Karabelsky A.** Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes. *Viruses.* . doi: 10.3390/v13071271. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2021; 13: 1271. <https://pubmed.ncbi.nlm.nih.gov/34209981/>.
27. **Propper D.J., Balkwill F.R.** Harnessing cytokines and chemokines for cancer therapy. *Nat. Rev. Clin. Oncol.* . doi: 10.1038/s41571-021-00588-9. [DOI] [PubMed] [Google Scholar]. [Online], 2022; 19: 237–253. <https://www.nature.com/articles/s41571-021-00588-9>.
28. **Sadeghzadeh M., Bornehdeli S., Mohahammadrezakhani H., Abolghasemi M., Poursaei E., Asadi M., Zafari V., Aghebati-Maleki L., Shanebandi D.** Dendritic cell therapy in cancer treatment; the state-of-the-art. *Life Sci.* doi: 10.1016/j.lfs.2020.117580. [DOI] [PubMed] [Google Scholar]. [Online], 2020; 254: 117580. <https://linkinghub.elsevier.com/retrieve/pii/S0024320520303283>.
29. **Liu M., Li L., Jin D., Liu Y.** Nanobody—A versatile tool for cancer diagnosis and therapeutics. *WIREs Nanomed. Nanobiotechnol.* doi: 10.1002/wnan.1697. [DOI] [PubMed] [Google Scholar]. [Online], 2021; 13: e1697. <https://pubmed.ncbi.nlm.nih.gov/33470555/>.
30. **Winkle M., El-Daly S.M., Fabbri M., Calin G.A.** Noncoding RNA therapeutics—Challenges and potential solutions. *Nat. Rev. Drug Discov.* . doi: 10.1038/s41573-021-00219-z. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2021; 20: 629–651. <https://www.nature.com/articles/s41573-021-00219-z>.
31. **Abd-Aziz N., Poh C.L.** . Development of oncolytic viruses for cancer therapy. *Transl. Res.* doi: 10.1016/j.trsl.2021.04.008. [DOI] [PubMed] [Google Scholar]. [Online], 2021; 237: 98–123. <https://pubmed.ncbi.nlm.nih.gov/33905949/>.
32. **Hu J., Cao J., Topatana W., Juengpanich S., Li S., Zhang B., Shen J., Cai L., Cai X., Chen M.** Targeting mutant p53 for cancer therapy: Direct and indirect strategies. *J. Hematol. Oncol.* doi: 10.1186/s13045-021-01169-0. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2021; 14: 1–19. <https://jhoonline.biomedcentral.com/articles/10.1186/s13045-021-01169-0>.
33. **Setton J., Zinda M., Riaz N., Durocher D., Zimmermann M., Koehler M., Reis-Filho J.S., Powell S.N.** Synthetic Lethality in Cancer Therapeutics: The Next Generation. *Cancer Discov.* doi: 10.1158/2159-8290.CD-20-1503. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2021; 11: 1626–1635. <https://pubmed.ncbi.nlm.nih.gov/33795234/>.
34. **Kaur H., Kesharwani P.** Advanced nanomedicine approaches applied for treatment of skin carcinoma. *J. Control. Release.* . doi: 10.1016/j.jconrel.2021.08.003. [DOI] [PubMed]

- [Google Scholar]. [Online], 2021; 337: 589–611. <https://www.sciencedirect.com/science/article/abs/pii/S0168365921004028?via%3Dihub>.
35. **Yadav A., Singh S., Sohi H., Dang S.** Advances in Delivery of Chemotherapeutic Agents for Cancer Treatment. *AAPS PharmSciTech*. doi: 10.1208/s12249-021-02174-9. [DOI] [PubMed] [Google Scholar]. [Online] <https://link.springer.com/article/10.1208/s12249-021-02174-9>.
 36. **Moody T.W., Lee L., Ramos-Alvarez I., Iordanskaia T., Mantey S.A., Jensen R.T. Bombesin.** 25. Moody T.W., Lee L., Ramos-Alvarez I., Iordanskaia T., Mantey S.A., Jensen R.T. Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy. *Front. Endocrinol.* doi: 10.3389/fendo.2021.728088. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online] <https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.728088/full>.
 37. **Shamseddine A.A., Burman B., Lee N.Y., Zamarin D., Riaz N.** Tumor Immunity and Immunotherapy for HPV-Related Cancers. *Cancer Discov.* doi: 10.1158/2159-8290.CD-20-1760. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2021; 11: 1896–1912. <https://aacrjournals.org/cancerdiscovery/article-abstract/11/8/1896/666188/Tumor-Immunity-and-Immunotherapy-for-HPV-Related?redirectedFrom=fulltext>.
 38. **Chaurasiya S., Fong Y.** Viroimmunotherapy for breast cancer: Promises, problems and future directions. *Cancer Gene Ther.* doi: 10.1038/s41417-020-00265-6. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2020; 28: 757–768. <https://www.nature.com/articles/s41417-020-00265-6>.
 39. **Subhan A., Attia S.A., Torchilin V.P.** Advances in siRNA delivery strategies for the treatment of MDR cancer. *Life Sci.* doi: 10.1016/j.lfs.2021.119337. [DOI] [PubMed] [Google Scholar]. [Online], 2021; 274: 119337. <https://www.sciencedirect.com/science/article/abs/pii/S0024320521003222?via%3Dihub>.
 40. **Gupta P., Neupane Y.R., Parvez S., Kohli K.** Recent advances in targeted nanotherapeutic approaches for breast cancer management. *Nanomedicine.* doi: 10.2217/nmm-2021-0281. [DOI] [PubMed] [Google Scholar]. [Online], 2021; 16: 2605–2631. <https://www.tandfonline.com/doi/full/10.2217/nmm-2021-0281>.
 41. **Talib W.H., Mahmud A.I., Kamal A., Rashid H.M., Alashqar A., Khater S., Jamal D., Waly M.** Ketogenic Diet in Cancer Prevention and Therapy: Molecular Targets and Therapeutic Opportunities. *Curr. Issues Mol. Biol.* doi: 10.3390/cimb43020042. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2021; 43: 42. <https://www.mdpi.com/1467-3045/43/2/42>.
 42. **Tajan M., Vousden K.H.** Dietary Approaches to Cancer Therapy. *Cancer Cell.* doi: 10.1016/j.ccell.2020.04.005. [DOI] [PubMed] [Google Scholar]. [Online], 2020; 37: 767–785. <https://pubmed.ncbi.nlm.nih.gov/32413275/>.
 43. **Mani S., Swargiary G., Tyagi S., Singh M., Jha N.K., Singh K.K.** Nanotherapeutic approaches to target mitochondria in cancer. *Life Sci.* doi: 10.1016/j.lfs.2021.119773. [DOI] [PubMed] [Google Scholar]. [Online], 2021; 281: 119773. <https://www.sciencedirect.com/science/article/abs/pii/S0024320521007591?via%3Dihub>.
 44. **Lu H., Wang Q., Liu W., Wen Z., Li Y.** Precision strategies for cancer treatment by modifying the tumor-related bacteria. *Appl. Microbiol. Biotechnol.* doi: 10.1007/s00253-021-11491-9. [DOI] [PubMed] [Google Scholar]. [Online], 2021; 105: 6183–6197. <https://pubmed.ncbi.nlm.nih.gov/34402938/>.
 45. **Zhang Q., Li L.** Photodynamic combinational therapy in cancer treatment. *J. BUON Off. J. Balk. Union Oncol.* [PubMed] [Google Scholar]. [Online], 2018; 23: 561–567. <https://pubmed.ncbi.nlm.nih.gov/30003719/>.
 46. **Dirisala A., Osada K., Chen Q., Tockary T.A., Machitani K., Osawa S., Liu X., Ishii T., Miyata K., Oba M., et al.** Optimized rod length of polyplex micelles for maximizing transfection efficiency and their performance in systemic gene therapy against stroma-rich pancreatic tumors. doi: 10.1016/j.biomaterials.2014.03.037. [DOI] [PubMed] [Google Scholar]. [Online], 2014; 35: 5359–5368. <https://www.sciencedirect.com/science/article/abs/pii/S0142961214002841?via%3Dihub>.
 47. **Tockary T.A., Foo W., Dirisala A., Chen Q., Uchida S., Osawa S., Mochida Y., Liu X., Kinoh H., Cabral H., et al.** Single-Stranded DNA-Packaged Polyplex Micelle as Adeno-Associated-Virus-Inspired Compact Vector to Systemically Target Stroma-Rich Pancreatic Cancer. *ACS Nano.* doi: 10.1021/acsnano.9b04676. [DOI] [PubMed] [Google Scholar]. [Online], 2019; 13: 12732–12742. <https://pubs.acs.org/doi/10.1021/acsnano.9b04676>.
 48. **Mishra B., Patel B.B., Tiwari S.** Colloidal nanocarriers: A review on formulation technology, types and applications toward targeted drug delivery. *Nanomed. Nanotechnol. Biol. Med.* doi: 10.1016/j.nano.2009.04.008. [DOI] [PubMed] [Google Scholar]. [Online], 2010; 6: 9–24. <https://www.sciencedirect.com/science/article/abs/pii/S0927776513005146?via%3Dihub>.
 49. **V., Torchilin.** Tumor delivery of macromolecular drugs based on the EPR effect. *Adv. Drug Deliv. Rev.* doi: 10.1016/j.addr.2010.03.011. [DOI] [PubMed] [Google Scholar]. [Online], 2011; 63:

- 131–135.
<https://www.sciencedirect.com/science/article/abs/pii/S0169409X10000803?via%3Dihub>.
50. **Wang X.D., Guo B., Zhai B., Yang B., Fan H., Lu X.C., Li S.X., Zhu H.L.** Doxorubicin Hydrochloride Liposome-Based CHOP Regimen in the Initial Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Study. *Zhongguo Shi Yan Xue Ye Xue Za Zhi*. doi: 10.19746/j.cnki.issn.1009-2137.2021.04.018. [DOI] [PubMed] [Google Scholar]. [Online], 2021; 29: 1136–1140.
<https://pubmed.ncbi.nlm.nih.gov/34362493/>.
 51. **Rosenblum D., Joshi N., Tao W., Karp J.M., Peer D.** Progress and challenges towards targeted delivery of cancer therapeutics. *Nat. Commun.* . doi: 10.1038/s41467-018-03705-y. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2018; 9: 1410.
<https://www.nature.com/articles/s41467-018-03705-y>.
 52. **Li B., Li Q., Mo J., Dai H.** Drug-Loaded Polymeric Nanoparticles for Cancer Stem Cell Targeting. *Front. Pharmacol.* . doi: 10.3390/pharmaceutics12040298. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2020; 12: 298.
<https://www.mdpi.com/1999-4923/12/4/298>.
 53. **El-Say K.M., El-Sawy H.S.** Polymeric nanoparticles: Promising platform for drug delivery. *Int. J. Pharm.* doi: 10.1016/j.ijpharm.2017.06.052. [DOI] [PubMed] [Google Scholar]. [Online], 2017; 528: 675–691.
<https://www.sciencedirect.com/science/article/abs/pii/S0378517317305604?via%3Dihub>.
 54. **Avramović N., Mandić B., Savić-Radojević A., Simić T.** Polymeric Nanocarriers of Drug Delivery Systems in Cancer Therapy. *Pharmaceutics*. doi: 10.3390/pharmaceutics12040298. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2020; 12: 298.
<https://pmc.ncbi.nlm.nih.gov/articles/PMC7238125>
 55. **Rashedi J., Haghjo A.G., Abbasi M.M., Tabrizi A.D., Yaqoubi S., Sanajou D., Ashrafi-Jigheh Z., Namvaran A., Mohammadi A., Khoshraj J.M., et al.** Anti-tumor Effect of Quercetin Loaded Chitosan Nanoparticles on Induced Colon Cancer in Wistar Rats. *Adv. Pharm. Bull.* doi: 10.15171/apb.2019.048. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2019; 9: 409–415.
<https://apb.tbzmed.ac.ir/Article/apb-26463>.
 56. **Abdel-Hakeem M.A., Mongy S., Hassan B., Tantawi O.I., Badawy .** Curcumin Loaded Chitosan- Protamine Nanoparticles Revealed Antitumor Activity Via Suppression of NF-κB, Proinflammatory Cytokines and Bcl-2 Gene Expression in the Breast Cancer Cells. *J. Pharm. Sci.* doi: 10.1016/j.xphs.2021.06.004. [DOI] [PubMed] [Google Scholar]. [Online], 2021; 110: 3298–3305.
[https://jpharmsci.org/article/S0022-3549\(21\)00294-X/abstract](https://jpharmsci.org/article/S0022-3549(21)00294-X/abstract).
 57. **Guo Z., Wang F., Di Y., Yao L., Yu X., Fu D., Li J., Jin C.** Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression. *Int. J. Nanomed.* doi: 10.2147/IJN.S166769. doi: 10.2147/IJN.S166769. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2018; 13: 4869–4880.
<https://www.dovepress.com/antitumor-effect-of-gemcitabine-loaded-albumin-nanoparticle-on-gemcита-peer-reviewed-fulltext-article-IJN>.
 58. **Khella K.F., El Maksoud A.I.A., Hassan A., Abdel-Ghany S.E., Elsanhoty R.M., Aladhadh M.A., Abdel-Hakeem M.A.** arnosic Acid Encapsulated in Albumin Nanoparticles Induces Apoptosis in Breast and Colorectal Cancer Cells. *Molecules*. doi: 10.3390/molecules27134102. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2022; 27: 4102.
<https://www.mdpi.com/1420-3049/27/13/4102>.
 59. **Gülsu A., Kılıç B., Alper M.** Paclitaxel Delivery by Cationic Gelatin Nanoparticles. *ChemistrySelect*. doi: 10.1002/slct.202103495. [DOI] [Google Scholar]. [Online], 2022; 7: e202103495.
<https://chemistry-europe.onlinelibrary.wiley.com/doi/epdf/10.1002/slct.202103495>.
 60. **Li Q., Liu X., Yan W., Chen Y.** Antitumor effect of poly lactic acid nanoparticles loaded cisplatin and chloroquine on the oral squamous cell carcinoma. *Aging*. doi: 10.18632/aging.202297. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2020; 13: 2593–2603.
<https://www.aging-us.com/article/202297/text>.
 61. **Auzenne E., Ghosh S.C., Khodadadian M., Rivera B., Farquhar D., Price R.E., Ravoori M., Kundra V., Freedman R.S., Klostergaard J.** Hyaluronic Acid- Paclitaxel: Antitumor Efficacy against CD44(+) Human Ovarian Carcinoma Xenografts. *Neoplasia*. doi: 10.1593/neo.07229. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2007; 9: 479–486.
<https://www.sciencedirect.com/science/article/pii/S1476558607800042?via%3Dihub>.
 62. **Ahmad N., Ahmad R., Alam A., Ahmad F.** Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. *Chem. Central J.* doi: 10.1186/s13065-018-0434-1. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2018; 12: 1–14.
<https://bmcchem.biomedcentral.com/articles/10.1186/s13065-018-0434-1>.
 63. **Jin M., Jin G., Kang L., Chen L., Gao Z., Huang W.** Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes. *Int. J. Nanomed.* doi: 10.2147/IJN.S161426. [DOI] [PMC free article]

- [PubMed] [Google Scholar]. [Online], 2018; 13: 2405–2426. <https://www.dovepress.com/smart-polymeric-nanoparticles-with-ph-responsive-and-peg-detachable-pr-peer-reviewed-fulltext-article-IJN>.
64. **Crozier J.A., Advani P.P., LaPlant B., Hobday T., Jaslowski A.J., Moreno-Aspitia A., Perez E.A.** N0436 (Alliance): A Phase II Trial of Irinotecan with Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. *Clin. Breast Cancer*. doi: 10.1016/j.clbc.2015.08.002. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2015; 16: 23–30. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4698217/>.
 65. **Guo J., Gao X., Su L., Xia H., Gu G., Pang Z., Jiang X., Yao L., Chen J.,** Chen H. Aptamer-functionalized PEG–PLGA nanoparticles for enhanced anti-glioma drug delivery. *Biomaterials*. doi: 10.1016/j.biomaterials.2011.07.004. [DOI] [PubMed] [Google Scholar]. [Online], 2011; 32: 8010–802. <https://linkinghub.elsevier.com/retrieve/pii/S0142961211007757>.
 66. **A.S., Chauhan.** Dendrimers for Drug Delivery. *Molecules*, 2018; 23: 938. doi: 10.3390/molecules23040938. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online] <https://www.mdpi.com/1420-3049/23/4/938>.
 67. **de Groot F.M.H., Albrecht C., Koekkoek R., Beusker P.H., Scheeren H.W.** “Cascade-Release Dendrimers” Liberate All End Groups upon a Single Triggering Event in the Dendritic Core. *Angew. Chem. Int. Ed.* doi: 10.1002/anie.200351942. [DOI] [PubMed] [Google Scholar]. [Online], 2003; 42: 4490–4494. <https://onlinelibrary.wiley.com/doi/10.1002/anie.200351942>.
 68. **Lai P.-S., Lou P.-J., Peng C.-L., Pai C.-L., Yen W.-N., Huang M.-Y., Young T.-H., Shieh M.-J.** Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy. *J. Control. Release*. doi: 10.1016/j.jconrel.2007.06.012. [DOI] [PubMed] [Google Scholar]. [Online], 2007; 122: 39–46. <https://www.sciencedirect.com/science/article/abs/pii/S0168365907002957?via%3Dihub>.
 69. **Malam Y., Loizidou M., Seifalian A.M.** Liposomes and nanoparticles: Nanosized vehicles for drug delivery in cancer. *Trends Pharmacol. Sci.* doi: 10.1016/j.tips.2009.08.004. [DOI] [PubMed] [Google Scholar]. [Online], 2009; 30: 592–599. [https://www.cell.com/trends/pharmacological-sciences/abstract/S0165-6147\(09\)00137-0?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0165614709001370%3Fsho%20wall%3Dtrue](https://www.cell.com/trends/pharmacological-sciences/abstract/S0165-6147(09)00137-0?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0165614709001370%3Fsho%20wall%3Dtrue).
 70. **Hallan S.S., Kaur P., Kaur V., Mishra N., Vaidya B.** Lipid polymer hybrid as emerging tool in nanocarriers for oral drug delivery. *Artif. Cells Nanomed. Biotechnol.* doi: 10.3109/21691401.2014.951721. [DOI] [PubMed] [Google Scholar]. [Online], 2016; 44: 334–349. <https://www.tandfonline.com/doi/full/10.3109/21691401.2014.951721>.
 71. **Stella B., Peira E., Dianza C., Gallarate M., Battaglia L., Gigliotti C.L., Boggio E., Dianza U., Dosio F.** Development and Characterization of Solid Lipid Nanoparticles Loaded with a Highly Active Doxorubicin Derivative. *Nanomaterials*. doi: 10.3390/nano8020110. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2018; 8: 110. <https://www.mdpi.com/2079-4991/8/2/110>.
 72. **Hanafy N.A.N., El-Kemary M., Leporatti S.** Micelles structure development as a strategy to improve smart cancer therapy. *Cancers*. doi: 10.3390/cancers10070238. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2018; 10: 238. <https://www.mdpi.com/2072-6694/10/7/238>.
 73. **Siddiqi A., Herdes C.** Water effect in the reverse micellar formation of docusate sodium. A coarse-grained molecular dynamics approach. *Fluid Phase Equilibria*. doi: 10.1016/j.fluid.2022.113469. [DOI] [Google Scholar]. [Online], 2022; 559: 113469. <https://www.sciencedirect.com/science/article/pii/S0378381222000917?via%3Dihub>.
 74. **Mandal A., Bisht R., Rupenthal I.D., Mitra A.K.** Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies. *J. Control. Release*. doi: 10.1016/j.jconrel.2017.01.012. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2017; 248: 96–116. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5319397/>.
 75. **Shen Y., Li W. HA/HSA.** co-modified erlotinib–albumin nanoparticles for lung cancer treatment. *Drug Des. Dev. Ther.* doi: 10.2147/DDDT.S169734. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2018; 12: 2285–2292. <https://www.dovepress.com/hahsa-co-modified-erlotinib-albumin-nanoparticles-for-lung-cancer-trea-peer-reviewed-fulltext-article-DDDT>.
 76. **Costa P.M., Bourgognon M., Wang J.T.-W., Al-Jamal K.T.** Functionalised carbon nanotubes: From intracellular uptake and cell-related toxicity to systemic brain delivery. *J. Control. Release*. doi: 10.1016/j.jconrel.2016.09.033. [DOI] [PubMed] [Google Scholar]. [Online], 2016; 241: 200–219. <https://www.sciencedirect.com/science/article/pii/S0168365916308513?via%3Dihub>.
 77. **Tavakolifard S., Biazar E., Pourshamsian K., Moslem M.H.** synthesis and evaluation of single-wall carbon nanotube-paclitaxel-folic acid conjugate as an anti-cancer targeting agent. *Artif. Cells Nanomed. Biotechnol.* doi: 10.3109/21691401.2015.1019670. [DOI] [PubMed] [Google Scholar]. [Online], 2016; 44: 1247–1253. <https://www.tandfonline.com/doi/full/10.3109/21691401.2015.1019670>.

78. **Hastrup J., Leandro L., Akopian N.** All-optical charging and charge transport in quantum dots. *Sci. Rep.* doi: 10.1038/s41598-020-71601-x. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2020; 10: 1–6. <https://www.nature.com/articles/s41598-020-71601-x>.
79. **Freeman R., Liu X., Willner I.** Chemiluminescent and Chemiluminescence Resonance Energy Transfer (CRET) Detection of DNA, Metal Ions, and Aptamer–Substrate Complexes Using Hemin/G-Quadruplexes and CdSe/ZnS Quantum Dots. *J. Am. Chem. Soc.* doi: 10.1021/ja202639m. [DOI] [PubMed] [Google Scholar]. [Online], 2011; 133: 11597–11604. <https://pubs.acs.org/doi/10.1021/ja202639m>.
80. **Gao Y., Gao D., Shen J., Wang Q.** A Review of Mesoporous Silica Nanoparticle Delivery Systems in Chemo-Based Combination Cancer Therapies. *Front. Chem.* doi: 10.3389/fchem.2020.598722. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2020; 8: 598722. <https://www.frontiersin.org/journals/chemistry/article/s10.3389/fchem.2020.598722/full>.
81. **Wang Y., Zhao Q., Han N., Bai L., Li J., Liu J., Che E., Hu L., Zhang Q., Jiang T., et al.** Mesoporous silica nanoparticles in drug delivery and biomedical applications. *Nanomed. Nanotechnol. Biol. Med.* doi: 10.1016/j.nano.2014.09.014. [DOI] [PubMed] [Google Scholar]. [Online] <https://www.sciencedirect.com/science/article/abs/pii/S1549963414005462?via%3Dihub>.
82. **von Maltzahn G., Park J.-H., Agrawal A., Bandaru N.K., Das S.K., Sailor M.J., Bhatia S.N.** Computationally Guided Photothermal Tumor Therapy Using Long-Circulating Gold Nanorod Antennas. *Cancer Res.* doi: 10.1158/0008-5472.CAN-08-4242. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2009; 69: 3892–3900. <https://doi.org/10.1158/0008-5472.CAN-08-4242>.
83. **Chang Y., Liu N., Chen L., Meng X., Liu Y., Li Y., Wang J.** Synthesis and characterization of DOX- conjugated dendrimer-modified magnetic iron oxide conjugates for magnetic resonance imaging, targeting, and drug delivery. *J. Mater. Chem.* doi: 10.1039/c2jm16792a. [DOI] [Google Scholar]. [Online], 2012; 22: 9594–9601. <https://pubs.rsc.org/en/content/articlelanding/2012/jm/c2jm16792a>.
84. **Patil Y., Sadhukha T., Ma L., Panyam J.** Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. *J. Control. Release.* doi: 10.1016/j.jconrel.2009.01.021. [DOI] [PubMed] [Google Scholar]. [Online], 2009; 136: 21–29. <https://www.sciencedirect.com/science/article/abs/pii/S0168365909000819?via%3Dihub>.
85. **Singh S.P., Sirbaiya A.K., Mishra A.** Bioinspired Smart Nanosystems in Advanced Therapeutic Applications. *Pharm. Nanotechnol.* doi: 10.2174/2211738507666190425122822. [DOI] [PubMed] [Google Scholar]. [Online], 2019; 7: 246–256. <https://www.mdpi.com/2072-6694/11/5/640>.
86. **Yoo J., Park C., Yi G., Lee D., Koo H.** Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems. *Cancers.* doi: 10.3390/cancers11050640. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2019; 11: 640. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6562917/>.
87. **Sheikh A., Md S., Kesharwani P.** Aptamer grafted nanoparticle as targeted therapeutic tool for the treatment of breast cancer. *Biomed. Pharmacother.* doi: 10.1016/j.biopha.2021.112530. [DOI] [PubMed] [Google Scholar]. [Online], 2022; 146: 112530. <https://www.sciencedirect.com/science/article/pii/S0753332221013172?via%3Dihub>.
88. **Gan C.W., Feng S.-S.** Transferrin-conjugated nanoparticles of Poly(lactide)-d- α -Tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood–brain barrier. *Biomaterials.* doi: 10.1016/j.biomaterials.2010.06.053. [DOI] [PubMed] [Google Scholar]. [Online], 2010; 31: 7748–7757. doi: 10.1016/j.biomaterials.2010.06.053. [DOI] [PubMed] [Google Scholar].
89. **Wang Z., Tiruppathi C., Cho J., Minshall R.D., Malik A.B.** Delivery of nanoparticle-complexed drugs across the vascular endothelial barrier via caveolae. *IUBMB Life.* doi: 10.1002/iub.485. [DOI] [PMC free article] [PubMed] [Google Scholar]. [Online], 2011; 63: 659–667. <https://iubmb.onlinelibrary.wiley.com/doi/10.1002/iub.485>.
90. **V., Torchilin.** Tumor delivery of macromolecular drugs based on the EPR effect. *Adv. Drug Deliv. Rev.* doi: 10.1016/j.addr.2010.03.011. [DOI] [PubMed] [Google Scholar]. [Online], 2011; 63: 131–135. <https://www.sciencedirect.com/science/article/abs/pii/S0169409X10000803?via%3Dihub>.
91. **Lee H., Fonge H., Hoang B., Reilly R.M., Allen C.** The Effects of Particle Size and Molecular Targeting on the Intratumoral and Subcellular Distribution of Polymeric Nanoparticles. *Mol. Pharm.* doi: 10.1021/mp100038h. [DOI] [PubMed] [Google Scholar]. [Online], 2010; 7: 1195–1208. <https://pubs.acs.org/doi/10.1021/mp100038h>.
92. *In vitro and in vivo activities of verteporfin-loaded nanoparticles.* *J Control Release.* **Konan-Kouakou YN, Boch R, Gurny R, Allemann E.,** 2005.
93. *Organically modified silica nanoparticles co-encapsulating photosensitizing drug and aggregation-enhanced two-photon absorbing fluorescent dye aggregates for two-photon photodynamic therapy.* *J Am Chem Soc.* **Kim S,**

- Ohulchanskyy TY, Pudavar HE, Pandey RK, Prasad PN.**, 2007.
94. *Nanoparticles in photodynamic therapy: an emerging paradigm.* *Adv Drug Deliv Rev.* **Chatterjee DK, Fong LS, Zhang Y.**, 2008.
 95. *Molecular basis for target RNA recognition and cleavage by human RISC.* *Cell.* **Ameres SL, Martinez J, Schroeder R.**, 2007.
 96. *Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.* *Int J Nanomedicine.* **Miele E, Spinelli GP, Miele E, et al.**, 2012.
 97. *The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides.* *Biomaterials.* **Chirila TV, Rakoczy PE, Garrett KL, Lou X, Constable IJ. T.**, 2002.
 98. *Gold nanoparticles for the cytoplasmic delivery of siRNA to induce enhanced gene silencing.* *Chem Lett.* **Oishi M, Nakaogami J, Ishii T, Nagasaki Y. Smart PEGylated**, 2006.
 99. *Plasmonic photothermal therapy (PPTT) using gold nanoparticles.* *Lasers Med Sci.* **Huang X, Jain PK, El-Sayed IH, El-Sayed MA.**, 2008.
 100. *Synergistic enhancement of selective nanophotothermolysis with gold nanoclusters: potential for cancer therapy.* *Lasers Surg Med.* **Zharov VP, Galitovskaya EN, Johnson C, Kelly T.**, 2005.
 101. *Alexis F, Pridgen EM, Langer R, Farokhzad OC.* Nanoparticle technologies for cancer therapy. *Handb Exp Pharmacol.*: s.n., 2010.
 102. *Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers.* *Proc Natl Acad Sci U S A.* **Siegmund KD, Marjoram P, Woo YJ, Tavare S, Shibata D.**, 2009.
 103. **de la Zerda A, Bodapati S, Teed R, et al.** *Family of enhanced photoacoustic imaging agents for high-sensitivity and multiplexing studies in living mice.* *ACS Nano.*, 2012.
 104. **Gratton SE, Ropp PA, Pohlhaus PD, et al.** *The effect of particle design on cellular internalization pathways.* *Proc Natl Acad Sci U S A.*, 2008.
 105. **Liang G, Ren H, Rao J.** *A biocompatible condensation reaction for controlled assembly of nanostructures in living cells.* s.l. : Nat Chem., 2010.
 106. **Wong RM, Gilbert DA, Liu K, Louie AY.** *Rapid size-controlled synthesis of dextran-coated, 64Cu-doped iron oxide nanoparticles.* . s.l. : ACS Nano, 2012.
 107. **Cai W, Chen K, Li ZB, Gambhir SS.** *Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature.* *J Nucl Med.*, 2007.
 108. **Adriani G, de Tullio MD, Ferrari M, et al.** *The preferential targeting of the diseased microvasculature by disk-like particles.* *Biomaterials*, 2012.
 109. *Transient stealth coating of liver sinusoidal wall by anchoring two-armed PEG for retargeting nanomedicines.* *Sci. Adv.*, 2020; 6: eabb8133.
 110. **Dirisala A., Uchida S., Toh K., Li J., Osawa S., Tockary T.A., Liu X., Abbasi S., Hayashi K., Mochida Y., et al.**, 2020.
110. [Online]
<https://pdfs.semanticscholar.org/5ae5/a8dbd81aaf3aa080644e436be190b7e6d149.pdf>.